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“One of the first duties of the physician is to educate the masses not to take medicine” 
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BIS: bispectral index 
BMI: body mass index 
Ce: effect-site concentration 
CI: cardiac index 
Cm: measured concentration 
Cp: plasma concentration 
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Dia: invasive diastolic pressure 
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HD: haemodynamic 
HR: heart rate 
IV: intravenous 
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MDAPE: median absolute performance error 
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PE: prediction error 
Pk: pharmacokinetic 
PPV: pulse pressure variation 
SVV: stroke volume variation 
SV: stroke volume 
SVI: stroke volume index  
SVR: systemic vascular resistance 
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TCI: target-controlled infusion 








Anaesthesia and patient outcomes 
 
For long years, it was thought that anaesthetic management did not influence 
patient’s outcome. Surgical morbidity and long-term mortality were attributed to 
patient’s comorbidity, malignance of the disease, risk infection and type of surgery. 
Nowadays, there is an increasing evidence that intraoperative anaesthetic 
management can influence long-term patient outcomes1–6. In the last two decades, 
surgical mortality rates have been falling and, in part, this is due to a huge 
improvement in anaesthesia related factors and safety.  For an anaesthesiologist, 
perioperative care is no longer the simple fact of administrating the anaesthetic drug 
and maintaining the patient “asleep”. Direct-guided fluid therapy7,8, maintaining 
intraoperative normothermia, minimizing blood transfusion and avoiding low mean 
arterial pressure and deep hypnotic level are additional procedures the 
anaesthesiologist is responsible for and that will probably improve patient’s outcome 
and decrease surgical mortality9,10. 
Hypotension after induction of anaesthesia is quite common and more prevalent 
during the late post-induction period and before skin incision (5-10 minutes after), 
generally thought to be clinically irrelevant11. Nowadays, there is some evidence that 
small haemodynamic changes, such as hypotension, even for small periods, are 
associated with poor patient outcomes, because they have the potential to cause 
an ischemia–reperfusion injury which may be manifested as dysfunction of any vital 
organ, like acute kidney and myocardial injury3. Intra-operative management of 
hypotension is usually guided by conventional monitoring (systolic blood pressure and 
MAP) but these parameters could mask low levels of blood flow and oxygen delivery, 


















Figure 1: Propofol chemical structure: C12H18O. 
(Wikipedia) 
 
Since its introduction in clinical practice, the most commonly used intravenous (IV) 
anaesthetic is propofol14, an alkylphenol (2,6-diisopropylphenol) currently formulated 
in a lipid emulsion. Propofol provides rapid onset and offset with context-sensitive 
decrement times of approximately 10 minutes when infused for less than 3 hours and 
of less than 40 minutes when infused for up to 8 hours. This "context-sensitive" drug 
half-life depends on a complex interaction between the rate of drug redistribution, 
the amount of drug accumulated in fat and the drug`s metabolism. Its mechanism of 
action is likely the enhancement of γ-aminobutyric acid (GABAA)- induced chloride 
currents. Propofol causes a dose-dependent decrease in arterial blood pressure 
through a decrease in cardiac output and systemic vascular resistance15,16; propofol 
also seems to decrease the reflex baroreceptor and reduces sympathetic nerve 
activity17,18, and produces moderate respiratory depression. A unique action of 
propofol is its antiemetic effect, even at concentrations less than those producing 
sedation. The metabolites of propofol are thought to be inactive and undergo renal 
elimination. Because clearance of propofol (>1.5 L/minute) (30ml/min-1/kg-1) exceeds 
hepatic blood flow, extrahepatic metabolism or extrarenal elimination may occur19. 
Extrahepatic metabolism has been confirmed during the anhepatic phase of 
patients receiving a transplanted liver with the determination of propofol metabolites 
after propofol administration in the absence of liver tissue. The most important 
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extrahepatic site of propofol metabolism is the kidney. Renal metabolism of propofol 
accounts for up to 30% of propofol clearance, and this explains the rapid clearance 
of propofol, which exceeds liver blood flow. The lungs also may play a role in 
extrahepatic propofol metabolism. In humans, a 20% to 30% decrease in propofol 
concentration measured across the lung exists with a higher concentration of the 
metabolite 2,6-diisopropyl 1,4-quinol on the arterial side of the circulation20,21. 
In general anaesthesia, patient inter-individual variability to predict the individual 
hypnotic drugs requirements or recovery time is still an interesting issue22. Some of the 
factors that influence the pharmacokinetics are well known since the 1990s, such as 
age, weight, gender and some physiologic parameters. After the publication of the 
human genome in 2003, pharmacogenetics has become an interesting instrument to 
understand genes and proteins variations, transforming the actual medicine in a 
personalised medicine23. There are some genes and polymorphisms that can alter 
hypnotic drugs pharmacodynamics. 
Pharmacokinetic models were developed to facilitate anaesthesia maintenance to 
drive infusion pumps, estimating plasmatic concentrations and effect-site 
concentrations using complex pharmacokinetic and pharmacodynamic models. In 
many clinical applications, propofol is administrated using target-controlled infusion 
(TCI) techniques and has proven to be satisfactorily accurate during anaesthesia24–27.  
Although not perfect, Schnider’s pharmacokinetic (Pk) model was the 
recommended to be used for TCI and advisory displays in Masui et al28 who 
compared the performance of three compartmental and one physiologically based 
recirculatory pharmacokinetic model for propofol: Schnider, Marsh, Schüttler and 
Upton, respectively. The two commonly used and commercially available Pk models 
in clinical practice in adults are the Schnider and Marsh. The first one, based on 
arterial blood sampling after intravenous bolus followed by continuous infusion in 
volunteers, uses as covariates of the metabolic clearance: age, height, lean body 
mass and total body weight29; it can be an advantage over the Marsh model, for 
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older patients, because it adjusts the dose and the infusion rate according to the 
patient’s age. In contrast, the Marsh model derives from the Pk variables of Gepts et 
al30 and sets compartmental volumes proportional to weight. Recently, this model 
showed some benefits in obese patients adjusting the body weight instead of using 
total body weight21. 
As indicated above, propofol Pk models incorporate covariates as age, weight and 
height but not physiological parameters as cardiac output (CO) variation. We know 
that anaesthesia induction and maintenance with propofol will probably cause 
arterial hypotension and, consequently, cardiac output variation14,15,17.  
Upton and Ludbrook31 developed a propofol Pk model based on a recirculatory and 
physiologically system. Recently, there were some modifications to Upton model with 
two assumptions: first, the parameter cardiac output varies with weight and second, 
also cardiac output decreases with age32. In theory, the Upton model would predict 
the effect of common haemodynamic disturbances such as congestive heart failure, 
severe blood loss, dehydration and other high and low cardiac output states but 
more studies are required to fine tune its performance, namely in the first minutes of 
infusion.  
The effect of cardiac output variation and the propofol pharmacokinetics was also 
being studied by Upton and Ludbrook33, that reported an inverse relationship 
between CO and propofol concentrations after a short propofol infusion in an ovine 
model. Myburgh34 observed the same relationship during longer propofol infusions in 
high-CO state induced with catecholamine infusion also in ovine. Kurita35 confirmed, 
in a swine model, that propofol plasma concentrations were inversely correlated to 
changes in CO during constant infusion. It must be highlighted that most of the 
published studies were performed in animal models, with no studies in humans. 
Recently, Keyl36 found that Schnider’s Pk model markedly underestimated propofol 
plasma concentrations in patients with impaired left ventricular function. It can be 
speculated that the difference between the predicted and measured propofol 
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concentration in patients with lower CO is most likely related to a decrease in total 
propofol clearance, but data is still needed to correlate CO or liver blood flow and 




Knee-chest positioning, a prone position variant 
 
Some surgical positioning, such as prone and knee-chest (KC) position (Figure 2), 
seems to change haemodynamic parameters and influence anaesthesia drugs 
pharmacokinetics, reducing propofol requirements38–42.  
 
Figure 2: Knee-chest surgical position, a variant from the prone position.  
(original drawing by Henrique Chaló) 
 
A study in awake volunteers reported a 15% to 20% reduction in CO after the knee-
chest position43, likely related to a decrease in venous return due to blood 
sequestration in lower limbs. 
Some years ago, we presented an observational retrospective study44 in consecutive 
patients selected from data basis in neurosurgery. All patients submitted to 
craniotomy for tumour surgery in either supine or prone position were included. In our 
study, patients in the prone position required less propofol concentrations. 
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Prone position and its variants had been developed as a result of the requirement for 
surgical access. It has been studied since the 1930s and extensively described by 
Anderton45 and Edgcombe46 who recognized physiological changes and associated 
complications. Some of the physiological changes are cardiovascular, as decreased 
cardiac output and inferior vena cava obstruction and respiratory, as changes in 
lung volumes and abnormal distribution of pulmonary blood flow and ventilation.  
The effects of the prone position and its variants on cerebral blood flow and cerebral 
oxygenation are also not well quantified47. Although cerebral oxygenation in 
anesthetized patients in the prone position can be maintained within safe margins, 
there is evidence of impairment of autoregulation48, and this might be reflected in 
low bispectral index (BIS) values. 
Major complications associated to prone position are: injuries in the central nervous 
system, as injuries from arterial occlusion, injuries from venous occlusion, air 
entrainment, cervical spine injury and undiagnosed space-occupying lesions; injuries 
to the peripheral nervous system, as peripheral nerve injury; pressure injuries; 
ophthalmic injury and embolic complications47,49,50. Accordingly to these changes 
and complications, soon there were many devices developed for patients submitted 
to surgery in prone position, with the purpose to attenuate these deleterious effects, 
such as specific body mattress; pelvic and shoulder supports; head and neck 
supports and protection for the face devices; and abdominal frames and mattress51. 
The knee-chest position is currently used in a very large number of surgical 
procedures. Anaesthesiologists must be prepared to anticipate and minimize 
predictable risks, like intraoperative hypotension periods due to cardiac output 
reduction to critical ischemic levels. Positioning patients in KC position following 






Technology and monitoring advances 
 
In the last 30 years, perioperative technology devices had a great progress, such as 
depth of anaesthesia and cerebral and tissue oxygen monitoring and minimally 
invasive cardiac output monitors12,52,53. Despite these technological advances, occult 
low levels of blood flow and oxygen delivery still happen in high-risk surgical patients. 
Monitoring of hypnotic depth of anaesthesia using digital processing techniques 
applied to the electroencephalogram (EEG), such as Bispectral Index monitor, is used 
worldwide to guide anaesthesia maintenance in high-risk patients. It is well known 
that elderly patients and patients with important comorbidities require less 
anaesthetic drugs than healthy young patients, therefore BIS monitoring is clinically 
useful to titrate anaesthetic drugs and avoid awareness risk in these patients54. 
For long years, pulmonary arterial catheter (PAC) was considered the gold standard 
for cardiac output monitoring in critically ill patients during anaesthesia procedures 
and intensive care units. The recent trend in cardiac output monitoring is minimally 
invasive such as arterial pulse contour and pulse power analysis methods. It is an 
easily and accurate alternative to PAC, as the minimally invasive devices have been 
compared with innumerable studies to PAC and compared to each other55–57. 
Clinical benefit of monitoring haemodynamic (HD) parameters in high-risk patients is 
widely known, as arterial pressure variations might not reflect cardiac output, tissue 
perfusion pressure and oxygen delivery. The objectives of HD monitoring are to assess 
and optimize cardiac function, in order to achieve and maintain adequate tissue 
perfusion, guiding fluid therapy and cardiovascular drugs. Also, study of the arterial 
pressure tracing serve not only to predict but also to assess the fluid response with 
pulse pressure variation (PPV) and stroke volume variation (SSV) parameters in 
ventilated patients58. Cyclic changes in intrathoracic pressure during respiratory cycle 
may influence ventricular filling when stroke volume is preload dependent. PPV and 
SSV are useful parameters consisting in locating patients in the Frank Starling curve, 
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namely when this reaches the plateau and fluids are given but there is no further 
increase in stroke volume. 
 
LiDCO rapid® (LiDCO Ltd., Cambridge, UK) 13,59–61 is a minimally invasive cardiac 
output monitor based on the principle that the stroke volume can be tracked 
continuously by analysis of the arterial pressure waveform, as this is a result of an 
interaction between stroke volume and the vascular structure. Pulse CO technique 
uses a standard peripheral arterial line to extract a pulse wave (the systolic and the 
diastolic part of the pressure curve) based on the assumption of mass/power 
conservation in a system, when there is a linear relationship between net power and 
net flow in the vascular system. The harmonic waveform analysis, because of its wave 
reflections in the vascular system, require an autocorrelation to determine the 
“change of power” caused by the heart55. The first LiDCO monitor used a lithium 
indicator dilution to calibrate the system, but latest LiDCO rapid® does not require 
external calibration and had demonstrated to be a clinical reliable continuous 
cardiac output monitor. There are many studies and reviews comparing this CO 
monitor to PAC and comparing to other minimally invasive CO monitors and results 
are satisfactory. Although, the utility of this kind of monitors is the patient’ s trend 
evaluation when anaesthesiologist may determinate baseline values, a minimally 
invasive CO monitor could be connected to the patient any time of the surgery or 
during the postoperative period. Vincent and Fagnoul62 wrote “The main reason why 
reliable cardiac output monitoring can be useful during surgery is to be able to 
establish a baseline for high-risk patients in whom complications, such as hypoxemia, 
tachycardia or oliguria, arise after the immediate postoperative period, and 
therapeutic interventions become more complex”. Introducing a CO monitor when 
patient complications had already happened can be disappointing and usefulness, 




Anaesthesiology education and simulation training 
 
Active learning strategies and simulation technologies are already used with medical 
students63,64 and residents65 and their benefits and advantages on students' learning 
cognitive and behavioural skills are well recognised66,67. Simulation-based learning 
can also be helpful to develop healthcare professional's knowledge, skills and 
attitudes while protecting patients from unnecessary risks68. Anesthesiologists 
pioneered the use of patient simulators in training programs all over the world69,70. 
Cardiovascular physiology can be simulated in mannequins but is limited to the 
simulator monitor curves, missing some important data that today is known as 
essential to fluid management in high-risk patients. This tool is important to train basic 
cardiovascular physiology but also haemodynamic variations during anaesthesia 
phases: induction, positioning, controlled hypotension and other surgical conditions 
associated with haemodynamic compromise (orthopaedic surgery, vascular surgery, 
major abdominal surgery).  
Anaesthesiologists and other healthcare professionals should be trained on their own 
monitors, so they can interpret easily their parameters and provide a better and safer 
healthcare71–73. A connection between a patient simulator and anaesthesia monitors, 








 …despite these great advances in patient monitoring, there are several surgical 
procedures in high-risk patients where low blood flow (cerebral and coronary) occurs, 
and may be undetected4. That is the reason why we decided to study the 
haemodynamic changes during anaesthesia induction and knee-chest positioning in 
neurosurgical patients and its influence in propofol pharmacokinetic variation in a TCI 






HYPOTHESIS AND OBJECTIVES 
 
Hypothesis 
The hypothesis of this study is that the fall in arterial blood pressure and cardiac 
output following induction and after positioning could be attenuated by reducing 
the propofol target concentrations administered trough target-controlled infusion 
anaesthesia in neurosurgical patients scheduled for lumbar spinal surgery in the knee-
chest position. 
 
We also hypothesized that propofol effect-site and plasmatic concentrations 
predicted by Schnider pharmacokinetic model would not be accurate when HD 
changes occurred, especially, after knee-chest positioning. Predicted propofol 
plasmatic concentration would differ from measured propofol concentration more 





The primary objective of this study was to assess whether reductions in propofol target 
concentrations applied immediately following loss of consciousness and immediately 
before positioning, would attenuate the HD changes associated with induction itself 
and knee-chest positioning. The haemodynamic changes were quantified by a 
minimally invasive cardiac output monitor, LiDCO rapid®. 
We design two different anaesthesia maintenance protocols to evaluate if 
protocolled reductions in propofol would attenuate the HD changes:  
- In a first set of patients (Phase 1), no propofol target concentration reductions 
were protocoled and the falls in cardiac output following induction and knee-
chest positioning were quantified. Anaesthesia was guided by depth of 
hypnosis (BIS) and clinical parameters and propofol effect-site concentrations 
were manually modified by the anaesthesiologist. 
- In a second set of patients (Phase 2), two propofol target concentration 
reductions, based on the data from the first set of patients, were applied. 
 
The secondary objective was to investigate the variation in propofol plasmatic 
concentrations, predicted by Schnider pharmacokinetic model, after LOC and, 
especially, after KC positioning, which represent anaesthesia periods with clinical 
relevant HD changes, and correlate them with measured propofol concentrations. 
 
Another learning aim was to develop an interface that would connect the patient 
simulator to the cardiac output monitor, LiDCO rapid®, for training anaesthesiologists 







A two-phase prospective cohort study of patients scheduled for lumbar spinal surgery 
in KC position was conducted following the Research Ethics Board (REB) approval 
and informed signed consent.  
A power analysis was conducted based on an expected CO variation between 
supine and KC position of 30%38 and an expected attenuation of 50% in the cardiac 
output fall, and the calculated number of patients to include in the study was 20 
subjects.  
Exclusion criteria were: severe ischemic heart disease, congestive heart failure, atrial 
fibrillation or flutter, Body Mass Index (BMI)>35, Glasgow Coma Scale<15 or dementia 
disease, history of drug abuse or addiction and patients who were administered pre-
operative midazolam. A careful physical examination was performed on each 
patient to exclude potentially difficult airway, ischemic peripheral arterial disease 




Anaesthesia, Monitoring and Equipment 
 
Once arrived at the operating room, all patients received a crystalloid intravenous 
infusion at 400mL/h till the end of anaesthesia induction and maintained at 200mL/h 
throughout the surgery.  
The standard monitored parameters in all patients were heart rate, ECG, peripheral 
arterial oxygen saturation measured by pulse oximetry, invasive blood pressure, depth 
of anaesthesia with bispectral index™ (BIS™ brain monitoring, Medtronic, USA), 
peripheral body temperature and neuromuscular block monitoring with train of four 
stimulation (TOF) on the right hand.  
A left radial artery catheter was placed with local anaesthesia before induction and 
LiDCO rapid® was connected to collect haemodynamic data every second:  
- Cardiac output (CO),  
- Cardiac index (CI),  
- Stroke volume (SV),  
- Stroke volume index (SVI),  
- Systemic vascular resistance (SVR),  
- Invasive systolic pressure (Sys),  
- Mean arterial pressure (MAP),  
- Invasive diastolic pressure (Dia),  
- Heart rate (HR),  
- Pulse pressure variation (PPV) 
- Stroke volume variation (SVV).  
This CO monitor does not require any calibration. In a separate computer, RugLoopII© 
software was used to drive the remifentanil and propofol pumps (AlarisTM Asena, BD, 
UK) and to collect data every 5’’, connected to the patient monitor (Aisys®, GE 
Healthcare, USA).  
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At this moment, we collected the first blood sample called “Baseline”, free of drugs or 
“Moment 0” and recorded all clinical and HD parameters described previously. Then, 
anaesthesia induction started with remifentanil (20μg/ml) by TCI to achieve and 
maintain an effect-site concentration target (Ce) of 2,5ng/ml (Minto 
pharmacokinetic Pk model). Propofol (1%) was then started at 200ml/h until loss of 
consciousness (LOC). LOC was considered when the patient failed to open his/her 
eyes following name calling and tapping on the forehead. At the moment of LOC, 
propofol infusion was stopped and the estimated effect-site concentration of 
propofol was noted. Schnider’s Pk model was used. The pump was then switched to 
TCI mode.  
From this moment on, the anaesthesia protocol in patients from phase 1 and phase 2 











PHASE 1 (P1): “maintain propofol” 
After LOC, propofol concentration was switched to TCI at a target Ce equal to the 
Ce at LOC. Maintenance of anaesthesia was guided by BIS (40-60) and HD 
parameters. Tracheal intubation was accomplished after the muscle relaxant 
administration (rocuronium 0,6mg/kg) and patients were mechanically ventilated 
with an O2/air mixture to achieve SpO2> 98%, tidal volume (~8ml/kg) and respiratory 
rate adjusted to normocapnic end-tidal CO2. Remifentanil Ce was switched to 
1ng/ml between intubation and surgical incision. Ephedrine boluses (5mg) were 
allowed when CO or SYS decreased more than 30% from baseline. 
 
The second blood sample was collected 10 minutes after LOC (Moment 1 or SP1) and 
then patients were positioned in KC position carefully, paying attention to all the 
compression points and using a ProneView® platform for the head. All the monitoring 
and anaesthetics infusions were continued.  
The third blood sample was collected and parameters were registered 10 minutes 
after performing KC position, before incision (Moment 2 or KC).  
During this phase, two blood samples were collected:  
Moment 1 or SP1: 10 minutes after LOC, with the patient in supine and drugs in 
steady-state; 
Moment 2 or KC: 10 minutes after KC positioning (KC), with drugs in steady-state.  
Before collecting the blood samples, HD parameters and BIS values were registered. 
At this point, the phase 1 study was completed. 
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PHASE 2 (P2): “reduce propofol”  
After LOC, propofol concentration was switched to TCI mode at a Ce target 
calculated using a formula developed by our group74 that relates the Ce of LOC with 
the Ce that results in maintaining BIS between 40 and 60: 
 
Propofol reduction (%) = 100 – (95.2-7.6 * Prop Ce at LOC). 
 
 
Tracheal intubation and ventilation were performed as described in phase 1. 
Remifentanil target Ce was changed to 1ng/ml between intubation and surgical 
incision.  
The second blood sample was collected 10 minutes after LOC (Moment 1 or SP1). A 
second reduction of propofol Ce was performed with the same magnitude as the 
CO variation observed on P1 patients and, 2 minutes later, the third blood sample 
was collected (Moment 1’ or SP2). Afterwards, patients were placed in KC position as 
described in P1. Ten minutes after KC positioning and before incision, the fourth blood 
sample was collected (Moment 2 or KC). 
During this phase, three blood samples were collected: 
Moment 1 or SP1: 10 minutes after LOC, patient in supine and drugs in steady-state; 
Moment 1’ or SP2: 2 minutes after the second propofol reduction, patient in supine 
and drugs in steady-state; 
Moment 2 or KC: 10 minutes after KC positioning, drugs in steady-state. 
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Before collecting the blood samples, HD parameters and BIS values were registered. 
At this point, the phase 2 study was completed.  
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Plasma propofol sampling 
 
During the study period, 3 ml arterial blood samples were collected from the left 
radial artery into heparin containing tubes for propofol and propofol metabolites 
quantification in the plasma according to the protocol. After blood collection the 
plasma was separated through centrifugation at 3000 rpm during 15 minutes and was 
immediately placed at -77ºC and stored until analysis. Propofol plasma 
concentrations as well as its free metabolites (quinol and quinone) were determined 
by gas chromatography mass spectrometry according to Guitton et al75 with some 
adjustments, as described in Silva et al76. 
Briefly, 50μ l internal standard thymol solution (0.01 mg/ml) and 1 ml water were 
added to 0.5-ml aliquot serum or propofol calibration standards. To this solution, 0.5 ml 
borate buffer (pH 9) was added and mixed by inversion. Then, 300μl chloroform: 
ethylacetate (70:30, v:v) were added and mixed for 20 min at 50 rpm, after which 1 l 
organic phase solution was injected into the gas chromatography-mass spectrometry 
injector in splitless mode at 250°C. The quantification of propofol was performed in a 
Varian CP-3800 gas chromatograph (Varian, Walnut Creek, CA) equipped with an 
ion trap mass detector (Varian Saturn 4000). The chromatographic column was a 
Varian Factor Four ms (30 m × 0.25 mm × 0.25 μm). The column temperature was 
programmed to 100°C (1 min), 15°C/min until 300°C (10 min). The detection of 
propofol and thymol was conducted in Full Scan mode, and the quantification 
performed by monitoring the characteristic mass-to-charge ratio (m/z) fragments of 
each molecule: for propofol, the m/z used were 178 and 163, and for thymol, the m/z 
used were 150 and 135. The retention times for each compound were, respectively, 
5.6 and 5.0 min. 
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For the calibration curve, the non-conjugated metabolites were chemically 
synthesized since these compounds are not commercially available. The purified 
metabolites (> 95%) were subsequently used as GC-MS standards. 
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Pharmacokinetic model performance 
 
The accuracy and bias of models predictions were calculated from differences 
between measured (Cm) and predicted (Cp) propofol concentration for each 




Median prediction error (MDPE) represents the median bias of the model and median 
absolute performance error (MDAPE) represents the median accuracy of the 
prediction, calculated for each moment and each phase. In literature,  values for 
MDPE less than 20% (-20 to 20%) and MDAPE between 20-40% are considered an 




Connection between the patient simulator and the LiDCO rapid® 
 
To connect the patient simulator to the haemodynamic monitor, firstly we had to 
assess both systems and design a communication channel between them. LiDCO 
monitor accepts as an input an analogue voltage varying between 0V and 5V and 
that every volt is directly proportional to a blood pressure (mmHg) value ranging from 
0 mmHg (0V) to 500 mmHg (5V). A Raspberry Pi 0 (Rpi0) with a WIFI chip integrated 
was needed and added to a digital analogue converter connected to the board. 
We designed a system that allowed us to collect, interpret and modify data, and 
feed it to the LiDCO rapid® monitor. We had developed a Python® script with three 





Statistical data analysis 
 
Data was collected from LiDCO rapid® and RugLoopII© equipments which acquired 
data independently and with different sampling frequencies. Therefore, 
synchronization between data from both equipments was mandatory for this study. 
Dedicated software was developed in Matlab® for this task. The delay between 
LiDCO rapid® and RugLoopII© series was estimated by the lag of the maximum cross-
correlation value between Sys acquired with both equipments. The optimum 
resampling of the RugLoopII© down to the same temporal basis as the LiDCO rapid® 
was that achieving the highest maximum cross-correlation value. The data 
synchronization was successful in all recordings as normalized cross-correlations 
between Sys time series acquired by both equipments were above 0,9 for all 
recordings (n=20). For data analysis, 1-minute duration windows were considered 
around each of the above defined study moments and the average of the observed 
values was computed for each window. The statistical analysis considered a full 
factorial model in a two-way mixed ANOVA analysis to compare the mean 
differences of the measured variables, considering the main effect “Moment” 
(between-subjects), the main effect “Phase” (within-subjects) and their interactions. 
The normality assumption was tested by Shapiro-Wilk test of normality and the 
sphericity assumption was investigated by the Mauchly's Test of sphericity. A p-value 
lower than 5% was considered as statistically significant. 
 
Further post-hoc testing (ANOVA and t-test with Bonferroni correction) was 
conducted to compare “Moments” and “Phases”. The assumption of homogeneity 
of variances was investigated with Levene’s test. Alternative non-parametric testing 
(Friedman, Wilcoxon Signed-Rank and Mann-Whitney U) were also conducted in 
order to investigate impact for any deviation from the assumptions of the parametric 
tests. In this analysis, the statistical conclusions at 5% level from parametric and non-
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parametric tests were concordant. Results per moment/phase are expressed as 





In this chapter, there will be presented the abstracts of the publications that resulted 
from the clinical investigation to the actual doctoral thesis, in spanish language, as 
required by the “Comisión de Doctorado y Posgrado, 15 de febrero de 2013”. 
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Introducción: La inducción anestésica está asociada a grandes variaciones 
hemodinámicas, incluso cuando es realizada a través de una perfusión guiada por 
concentraciones en el órgano diana (TCI, Target Controlled Infusion), en este caso, el 
cerebro, utilizando modelos farmacocinéticos (Pk). El posicionamiento quirúrgico en 
genupectoral provoca igualmente alteraciones cardiovasculares, en especial, 
diminución del gasto cardiaco (GC). Hoy en día, se cree que éstas variaciones 
podrían tener impacto en el resultado clínico del paciente y deberían ser evitadas. 
Objetivo: El objetivo de este estudio clínico es evaluar si las reducciones de las 
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concentraciones cerebrales de propofol aplicadas justo después de la inducción 
anestésica y antes del posicionamiento en genupectoral atenúan las alteraciones 
hemodinámicas asociadas. 
Métodos: Estudio prospectivo de cohortes realizado en dos fases que ha incluido 20 
pacientes propuestos para cirugía de columna lumbar en posicionamiento 
genupectoral. Los parámetros hemodinámicos se registraron en distintos momentos 
a través del monitor LiDCO rapid® y fueron comparados con el valor basal, antes de 
la inducción. La inducción se realizó con perfusión de propofol en modo TCI, hasta 
conseguir la pérdida de consciencia (LOC, loss of consciousness), y fué registrada la 
concentración cerebral del fármaco. Se diseñaron 2 protocolos de mantenimiento 
distintos, aplicados después de la inducción anestésica: en la fase 1 (n=9), la 
concentración cerebral de propofol de mantenimiento es igual a la concentración 
de LOC. Las variaciones del gasto cardiaco y otros parámetros hemodinámicos 
provocadas por la inducción y por el posicionamiento en genupectoral fueron 
cuantificadas. En la fase 2 (n=11), se planificaron 2 reducciones en la concentración 
cerebral de propofol para el mantenimiento anestésico con el objetivo de atenuar 
dichas variaciones hemodinámicas. La primera, calculada a través de una fórmula 
desarrollada por nuestro grupo de investigación, y la segunda reducción, 
proporcional a las alteraciones del gasto cardiaco cuantificadas en la primera fase. 
Resultados: En la fase 1, comparando el GC basal con el GC después de la 
inducción se observó una reducción significativa del 25.6%; comparando el basal 
con el post-posicionamiento en genupectoral, la reducción fué todavía más 
significativa, 38,4%. En la fase 2, comparando el GC basal con el GC después de la 
inducción también se observó una reducción significativa del 19,8%; el GC post-
posicionamiento en genupectoral se redujo significativamente un 46,9%. Entre las dos 
fases, no se observaron diferencias significativas en el GC ni en los valores del 
monitor de profundidad anestésica (BIS). Por otra parte, las variaciones del GC y de 
la presión arterial media no han sido correlacionables. En la fase 2, la concentración 
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cerebral estimada de propofol y el propofol infundido fueron significativamente 
menores (p<0,001).  
Conclusión: En ambas las fases se observó una diminución significativa del gasto 
cardiaco en todos los momentos, post-inducción y post-posicionamiento. Las 
reducciones programadas de las concentraciones de propofol se demostraron 
ineficaces en la atenuación de las variaciones hemodinámicas. El estudio 
comprueba que el posicionamiento en genupectoral podría ser un factor 
independiente responsable de estas alteraciones cardiovasculares. En pacientes de 
alto riesgo se cree que pequeñas variaciones hemodinámicas podrían alterar su 
desenlace quirúrgico, aumentando la morbimortalidad. Se alerta a los 
anestesiólogos y se sugiere la utilización de, además de la monitorización estándar, 
la monitorización de la profundidad anestésica y del gasto cardiaco en pacientes 




ARTICLE 2:                 (APPENDIX B) 
 
EFFECT OF HEMODYNAMIC CHANGES IN PLASMA PROPOFOL CONCENTRATIONS 
ASSOCIATED WITH KNEE-CHEST POSITION IN SPINAL SURGERY: A PROSPECTIVE STUDY 
Daniela Chalo 1, 2, Sara Pedrosa 2, Pedro Amorim3, Aura Silva 4, Paula Guedes de 
Pinho4, Rui Correia 5, Sonia Gouveia 6, 7 and Consuelo Sancho8 
 
1. Institute of Neurosciences of Castilla y Leon, INCyL, IBSAL, University of Salamanca, 
Salamanca, Spain;  
2. Anesthesiology Department, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal; 
3. Anesthesiology Department, Centro Hospitalar do Porto, Porto, Portugal; 
4. UCIBIO-REQUIMTE, Toxicology Laboratory, Biological Sciences Department, Faculty 
of Pharmacy of the University of Porto, Porto, Portugal; 
5. Anesthesiology Department, Anesthesiology Centre for Investigation, Centro 
Hospitalar do Porto, Porto, Portugal; 
6. Institute of Electronics and Informatics Engineering of Aveiro (IEETA), University of 
Aveiro, Aveiro, Portugal; 
7. Center for R&D in Mathematics and Applications (CIDMA), University of Aveiro, 
Aveiro, Portugal; 
8. Physiology and Pharmacology Department, INCyL, IBSAL, University of Salamanca, 
Salamanca, Spain. 




Introducción: La inducción y mantenimiento de una anestesia intravenosa con 
propofol puede realizarse a través de una perfusión guiada por concentraciones en 
el órgano diana (TCI, Target Controlled Infusion), en este caso, el cerebro, utilizando 
modelos farmacocinéticos (Pk). Además de los datos biométricos, existen otras 
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variables fisiológicas que podrán influenciar la farmacocinética del propofol, como 
por ejemplo, las variaciones del gasto cardíaco. Algunos posicionamientos 
quirúrgicos, como es la posición genupectoral, condicionan alteraciones 
importantes en las variables cardiovasculares, sobre todo, en el gasto cardíaco. 
Objetivos: El objetivo de este estudio clínico es evaluar la influencia de las 
variaciones del gasto cardíaco provocadas por la inducción anestésica y por el 
posicionamiento en genupectoral en las concentraciones plasmáticas reales de 
propofol, comparando éstas con las estimadas por el modelo farmacocinético (Pk) 
de Schnider. 
Métodos: Estudio prospectivo de cohortes realizado en dos fases que ha incluido 20 
pacientes propuestos para cirugía de columna lumbar en posicionamiento 
genupectoral. La inducción se realizó con perfusión de propofol en modo TCI, hasta 
alcanzar la concentración cerebral de pérdida de consciencia (LOC, loss of 
consciousness) y ésta fue registrada. Se han diseñado 2 protocolos de 
mantenimiento distintos, aplicados después de la inducción anestésica, ya descritos 
en la publicación anterior. Las concentraciones plasmáticas de propofol han sido 
medidas en varios momentos de ambas fases: después de la inducción anestésica y 
después del posicionamiento, y comparadas con las estimadas por el modelo. 
Resultados: En el momento después de la inducción, el modelo Pk de Schnider 
presenta un buen funcionamiento. Sin embargo, las concentraciones plasmáticas 
medidas después del posicionamiento, momento de gran variación del gasto 
cardiaco, han sido subestimadas por el modelo. Las reducciones intencionales en la 
concentración cerebral de propofol no resultaron como medida de atenuación de 
las variaciones hemodinámicas. En el momento después del posicionamiento, no se 
encontró correlación entre las concentraciones plasmáticas reales y las estimadas 
por el modelo Pk, siendo las reales significativamente superiores (p=0.013). Los valores 
del gasto cardiaco y del monitor de profundidad anestésica (BIS), por el contrario, 
decrecieron significativamente (p<0.001 y p=0.004, respectivamente). 
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Conclusión: El estudio ha demostrado que el modelo de Schnider subestima 
significativamente las concentraciones plasmáticas de propofol, asociadas a la 
diminución significativa del gasto cardiaco provocadas por el posicionamiento en 
genupectoral. Los anestesiólogos deben conocer las variaciones hemodinámicas de 
los posicionamientos quirúrgicos y, consecuentemente, las alteraciones 
farmacocinéticas asociadas, intentando minimizar sus efectos. Se reconoce mayor 
relevancia en pacientes de alto riesgo, sugiriendo la utilización de, además de la 
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Introducción: La fisiología cardiovascular puede ser enseñada y simulada con 
simuladores de alta fidelidad, sin embargo, estará siempre limitada a sus monitores, 
que no representan algunos de los parámetros hemodinámicos esenciales en el 
manejo de la fluidoterapia y de la terapia de decisión en pacientes críticos y de alto 
riesgo quirúrgico.  
Objetivo: El objetivo de este estudio fue proyectar e implementar un interfaz de 
comunicación entre un simulador de paciente y un monitor hemodinámico de gasto 
cardíaco mínimamente invasivo (LiDCO rapid®), esto es, un monitor que se conecta 
a un paciente real e interpreta la curva de presión arterial para extraer los datos 
hemodinámicos. 
Métodos:  Para conectar el simulador del paciente y el monitor hemodinámico, 
previamente, se ha a obtenido acceso a ambos sistemas y se ha diseñado un canal 
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de comunicación entre ellos. El monitor LiDCO rapid® acepta datos de voltaje 
analógicos variando entre 0V y 5V, siendo cada volt directamente proporcional al 
valor de la presión arterial (mmHg), siendo 0 mmHg = 0V y 500mmHg = 5V. Fue 
necesario desarrollar un conversor digital integrado a un procesador Raspberry Pi 0 
(Rpi0) con WIFI conectado al simulador, que permitiera recoger, interpretar y 
modificar los datos del simulador para trasmitirlos al monitor hemodinámico. Se 
desarrolló un guión en Python® con tres canales independientes y un regulador 
circular para controlar los datos entre ambos sistemas.  
Resultados: El monitor LiDCO rapid® ha recibido e interpretado los datos enviados 
como si de un paciente real se tratara, estimando así varios parámetros 
hemodinámicos, como por ejemplo, el gasto cardíaco, volumen sistólico, resistencias 
vasculares periféricas, variación de presión de pulso y variación de volumen sistólico.  
Conclusión: La conexión entre el simulador de paciente y el monitor LiDCO rapid® 
permite a éste, la creación de curvas arteriales y parámetros hemodinámicos para 
utilizar en escenarios clínicos simulados, donde residentes y adjuntos en 
anestesiología, así como estudiantes de medicina, podrán simular y practicar casos 
clínicos de inestabilidad cardiovascular, preparándolos para situaciones semejantes 
con pacientes reales, en un ambiente seguro y con su propio monitor 
hemodinámico. 







1. This study presents evidence that there is a relationship between 
haemodynamic changes and propofol pharmacokinetic variation during 
anaesthesia induction and knee-chest positioning in propofol target 
controlled infusion guided anaesthesia.  
2. Physicians should be aware that KC positioning is an independent factor to 
haemodynamic changes and intended reductions in propofol administration, 
immediately after LOC and before KC positioning, did not attenuate them. 
3. Planned propofol reductions did not avoid the underestimation error from 
Schnider’s pharmacokinetic model. Our study showed that measured 
propofol concentrations, after haemodynamic changes associated to knee-
chest position, were much higher than predicted. 
4. When placing patients in knee-chest position, bispectral index values 
decreased and measured propofol concentrations increased. Our results 
suggest that the cardiac output variation was responsible for the 
pharmacokinetic phenomenon described above. The increased plasma 
propofol concentrations may be due to a reduction in propofol distribution or 
due to reduced hepatic clearance during hypotensive episodes. 
5. We could not find a correlation between mean arterial pressure and cardiac 
output variation, wherefore, mean arterial pressure may not represent an 
accurate parameter to guide anaesthesia, vasoactive drugs or fluid therapy. 
6.  In high-risk patients placed in knee-chest position, anaesthesiologists must be 
aware of these haemodynamic and pharmacokinetic variations and, in 
addiction to standard monitoring, the use of depth of anaesthesia and 
cardiac output monitors may be considered to detect serious 
haemodynamic changes, to guide therapy and to minimize predictable risks. 
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7. The connection between the patient simulator and the CO monitor (LiDCO 
rapid®) was developed and tested. Further work is planned, in an educational 
area with a simulation program, to prepare anaesthesiologists and surgical 
teams to a structured and careful approach to surgical patients in knee-chest 
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OTHER WORKS RESULTING FROM THE STUDY 
 
A. ORAL PRESENTATIONS AND POSTERS 
 
Oral presentations 
Several presentations were made in many portuguese Anaesthesiology Departments 
presenting the haemodynamic monitor LiDCO Rapid® to anaesthesiologists and 





1. “Avaliação da alteração do débito cardíaco através do LiDCO Rapid® durante a 
indução anestésica e o posicionamento cirúrgico” 
Chaló D, Gouveia S, Amorim P 
Portuguese Society of Anaesthesiology (SPA) Annual Meeting, March 2011, Portugal. 
 
 
2. “Hemodynamic changes and propofol correlations during induction and knee-
chest position in propofol and remifentanil TCI guided anesthesia” 
Chaló D, Gouveia S, Silva A, Guedes P, Amorim P 
American Society of Anesthesiology (ASA) Annual Meeting, October 2011, EUA. 
 
 
3. “Hemodynamic Changes During Induction and Knee-Chest Positioning in Propofol 
and Remifentanil TCI Guided Anesthesia – How to compensate these changes?” 
Chaló D, Pedrosa S, Gouveia S, Amorim P 
American Society of Anesthesiology (ASA) Annual Meeting, October 2015, EUA. 
 
4. “Inconsistent correlation between MAP and cardiac output during anaesthesia 
induction and patient positioning” 
Chaló D, Pedrosa S, Gouveia S, Amorim P 
Euroanaesthesia 2018, The European Anaesthaesiology congress, Denmark.  
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5. “Non-invasive haemodynamic monitor in high fidelity patient simulator to facilitate 
learning of cardiovascular parameters to anaesthesia residents” 
Chalo ́ D, Marques J, Mendes H, Sancho C 
SESAM 2019 Annual Meeting, Society for Simulation in Europe, Scotland 
 
 
B. EDUCATIONAL PROGRAM 
 
 
Courses / Workshops 
 
1. “1st Postgraduate course for actualization in haemodynamic monitoring” 
Oral presentation: “Introduction to LiDCO”  
Instructor: Practical Clinical Cases in pigs 
Faculty of Medicine – University of Lisbon, Lisbon, Portugal, 2012 
 
2. Workshop “Principles of Haemodynamic monitoring” 
Oral presentation: “Introduction to LiDCO” 
Instructor: Practical Clinical Cases 
“O Norte da Anestesia” - International Anaesthesiology Congress, Oporto, Portugal, 
2013 
 
3. Workshop “Principles of Haemodynamic monitoring” 
Instructor: Practical Clinical Cases 
“O Norte da Anestesia” - International Anaesthesiology Congress, Oporto, Portugal, 
2017 
 
4. Workshop “Principles of Haemodynamic monitoring” 
Instructor: Practical Clinical Cases 
“O Norte da Anestesia” - International Anaesthesiology Congress, Oporto, Portugal, 
2019 
 
5. “Simulation workshop in advanced anaesthesia monitoring – from backstage 
to the clinical practice” 
Coordinators: Daniela Chaló and Pedro Amorim 
Annual meeting “Jornadas de Anestesiologia ao Centro IV” 
SIMULA- Simulation Clinical Centre of Aveiro University, Aveiro, Portugal, 2018 
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6. “Prone Positioning Masterclass: become an expert” 
Coordination: Victor Oliveira and Jan Cernovsky 
Oral presentation: “Challenging clinical cases in prone position” 
Instructor: Practical Clinical Cases 
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Propofol TCI Reductions Do Not Attenuate Significant Falls
in Cardiac Output Associated With Anesthesia Induction
and Knee-Chest Positioning in Spinal Surgery
Daniela Chaló, MD,*† Sara Pedrosa, MD,† Pedro Amorim, MD,‡ Sónia Gouveia, PhD,§
and Consuelo Sancho, PhD*
Background: Induction of anesthesia and the knee-chest position
are associated with hemodynamic changes that may impact pa-
tient outcomes. The aim of this study was to assess whether
planned reductions in target-controlled infusion propofol con-
centrations attenuate the hemodynamic changes associated with
anesthesia induction and knee-chest position.
Materilas and Methods: A total of 20 patients scheduled for
elective lumbar spinal surgery in the knee-chest position were
included. In addition to standard anesthesia monitoring, bis-
pectral index and noninvasive cardiac output (CO) monitoring
were undertaken. The study was carried out in 2 parts. In phase
1, target-controlled infusion propofol anesthesia was adjusted to
maintain BIS 40 to 60. In phase 2, there were 2 planned reduc-
tions in propofol target concentration: (1) immediately after loss
of consciousness—reduction calculated using a predefined for-
mula, and (2) before positioning—reduction equal to the average
percentage decrease in CO after knee-chest position in phase 1.
Changes from baseline in CO and other hemodynamic variables
following induction of anesthesia and knee-chest positioning
were compared.
Results: Induction of anesthesia led to decreases of 25.6% and
19.8% in CO from baseline in phases 1 and 2, respectively
(P< 0.01). Knee-chest positioning resulted in a further decrease
such that the total in CO reduction from baseline to 10 minutes
after positioning was 38.4% and 46.9% in phases 1 and 2, re-
spectively (P< 0.01). There was no difference in CO changes be-
tween phases 1 and 2, despite the planned reductions in propofol
during phase 2. There was no significant correlation between
changes in CO and mean arterial pressure.
Conclusions: Planned reductions in propofol concentration do
not attenuate anesthesia induction and knee-chest position-
related decreases in CO. The knee-chest position is an in-
dependent risk factor for decrease in CO. Minimally invasive CO
monitors may aid in the detection of clinically relevant hemo-
dynamic changes and guide management in anesthetized patients
in the knee-chest position.
Key Words: cardiac output, anesthesia induction, spinal surgery,
knee-chest position, hemodynamic variation, propofol TCI an-
esthesia, minimally invasive CO monitors
(J Neurosurg Anesthesiol 2020;32:147–155)
Induction of anesthesia is associated with important he-modynamic changes, but previous studies have mostly been
limited to assessment of blood pressure effects.1–3 In recent
years there have been significant technological advances in
perioperative monitoring,4 particularly in the development of
minimally invasive cardiac output (CO) monitors such as the
LIDCO rapid (LiDCO Ltd, Cambridge, UK).5–11 Unlike
previous devices, the LIDCO rapid requires neither lithium
dilution nor calibration; it uses nomograms based on an in-
dividual patient’s biometrics to estimate CO and stroke vol-
ume. This technology has seldom been used to assess
comprehensive hemodynamic changes during anesthesia-in-
duced loss of consciousness (LOC).12,13 Modern target-con-
trolled infusion (TCI) systems allow more precise titration of
induction and maintenance of intravenous anesthesia, as well
as modeling of plasma and cerebral drug concentrations.14,15
Together, these technological advances allow a more accurate
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and comprehensive assessment of the hemodynamic changes
associated with induction of anesthesia and patient posi-
tioning.
Even short durations of arterial hypotension during
anesthesia, and the subsequent ischemia-reperfusion, have
been associated with acute kidney injury, cardiac com-
plications, stroke, and increased 30-day and 1-year mor-
tality after noncardiac surgery.16–18 In procedures where
the surgical position may also cause reductions in blood
pressure and CO, patients may be exposed to an increased
risk of intraoperative hypotension that is sufficient to
precipitate critical tissue ischemia.
The knee-chest is a variant of the prone position
(Supplementary Digital Content 1, http://links.lww.com/
JNA/A96), and it may be a particular problem, as it reduces
venous return and CO.19,20 Physiological changes and
complications associated with surgical positioning, including
standard prone21 and knee-chest position, have been studied
since the 1930s and extensively reviewed elsewhere.22,23 The
prone position and its variants are currently used in a large
number of surgical procedures.24,25 Anesthesiologists must
be aware of the risks that they pose of substantial hemo-
dynamic variation and be prepared to anticipate and mini-
mize such changes.
We have previously observed that lower propofol
concentrations are required in patients in the prone posi-
tion compared with similar individuals in the supine po-
sition. Thus, in the present study, we hypothesized that the
reduction in blood pressure and CO associated with
the knee-chest position could be attenuated by reducing
the dose of propofol administered after induction of an-
esthesia but before positioning. We also hypothesized that
the use of TCI propofol would allow more controlled re-
ductions in propofol dose. The main aim of the study was
to assess whether reductions in TCI propofol concen-
trations applied promptly after LOC but before position-
ing would attenuate the hemodynamic changes associated
with anesthesia induction and knee-chest positioning.
MATERIALS AND METHODS
A 2-phase prospective cohort study of patients un-
dergoing elective lumbar spine surgery in the knee-chest
position with TCI propofol anesthesia was conducted
following Research Ethics Board approval and after re-
ceiving written informed consent. Patients with severe is-
chemic heart disease, congestive cardiac failure, atrial
fibrillation or flutter, body mass index > 35 kg/m2, Glas-
gow Coma Scale <15, dementia, history of drug abuse or
addiction, and chronic opioid consumption, and those
who were administered preoperative midazolam were ex-
cluded.
Anesthesia, Monitoring, and Equipment
All patients received a crystalloid intravenous in-
fusion at 400mL/h from arrival in the operating room
until the end of anesthesia induction, and, thereafter, at
200 mL/h until the end of surgery. Routine monitoring—
ECG, heart rate, peripheral arterial oxygen saturation
measured by pulse oximetry, invasive blood pressure,
bispectral index (BIS brain monitoring; Medtronic, Min-
neapolis, Minnesota), peripheral body temperature, and
neuromuscular block monitoring—was undertaken in all
patients. A left radial artery catheter was placed under
local anesthesia before induction of anesthesia. The LiD-
CO rapid monitor was connected via this cannula, and the
following hemodynamic data were collected every second:
CO, cardiac index, stroke volume, stroke volume index,
systemic vascular resistance, invasive systolic, diastolic,
and mean arterial blood pressure, heart rate, pulse pres-
sure variation, and stroke volume variation. A separate
computer connected via the patient monitor (Aisys; GE
Healthcare, Chicago, Illinois), RugLoopII software
(DEMED website; Temse, Belgium) was used to drive the
propofol and remifentanil infusion pumps (Alaris; Asena,
BD, UK) and to collect data every 5 minutes.
Immediately before induction of anesthesia, baseline
clinical and hemodynamic parameters were recorded; this
was defined as moment 0 (M0). Anesthesia was then in-
duced with TCI remifentanil (20 μg/mL) to achieve and
maintain an effect-site concentration target (Ce) of 2.5 ng/
mL (Minto pharmacokinetic model) and propofol (1%) at
200mL/h until LOC, determined as the moment when the
patient failed to open his/her eyes after being called by
name and tapped on the forehead. At the moment of
LOC, propofol infusion was stopped, and the estimated
Ce noted. The infusion pump was then immediately
switched to TCI mode using Schnider’s pharmacokinetic
model. From this moment onwards, the propofol admin-
istration protocols were different during phases 1 and 2.
These are outlined in detail below and illustrated in the
Figure 1.
Following induction of anesthesia and admin-
istration of muscle relaxants (rocuronium, 0.6 mg/kg), all
patients were intubated. Mechanical ventilation (tidal
volume, 8 mL/kg) with an O2/air mixture to achieve
SpO2> 98% was adjusted to maintain normocapnic end-
tidal carbon dioxide. Remifentanil Ce was switched to 1
ng/mL after intubation and before surgical incision.
Ephedrine boluses (5 mg) were allowed if CO or systolic
blood pressure decreased by > 30% from baseline in all
patients.
After placement in the knee-chest position, a Pro-
neView platform was used to support the head, and
compression points were carefully protected. All mon-
itoring and anesthetic infusions were continued during
positioning.
Experimental Protocol
The study was carried out in 2 parts. In phase 1, the
reductions in propofol Ce were not protocolized but tar-
geted to maintain BIS 40 to 60. The reductions in CO
following induction of anesthesia and knee-chest posi-
tioning were quantified. In a second group of patients—
phase 2—two planned reductions in propofol Ce were
applied, one immediately after LOC and the other before
patient positioning. Hemodynamic variables were com-
pared within individuals and also between the 2 phases.
All hemodynamic variables were collected with drugs in
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the steady-state and when the signal of the LiDCO rapid
was quantified as “good.”
Phase 1
After LOC, propofol administration was switched to
TCI mode at a target Ce equal to the Ce recorded at LOC.
Subsequent propofol administration was targeted to
maintain BIS 40 to 60 and stable hemodynamic parame-
ters. Data were recorded 10 minutes after LOC (before
positioning the patient), and this was defined as moment 1
(M1). Further data were recorded 10 minutes after the
patient was placed in the knee-chest position but before
skin incision, and this was defined as moment 2 (M2).
Phase 2
In phase 2, propofol was also switched to TCI mode
after LOC, but with a lower Ce target than in phase 1,
calculated using a formula previously developed by our
group (Supplemental Digital Content 2, http://links.lww.
com/JNA/A97). This formula relates the Ce at LOC with
the Ce that maintains BIS between 40 and 60, as follows:
PropofolReduction %ð Þ ¼ 0:75 100 95:2 7:6 ID½ ð Þ;
where ID= induction dose (ie, Ce at LOC)
A second reduction in propofol Ce was implemented
after M1. The magnitude of this reduction was equal to
the percentage decrease in CO during knee-chest posi-
tioning measured in phase 1. Further data were collected
2 minutes after the second reduction in propofol Ce in
phase 2, and this was defined as moment M1ʹ (M1ʹ). As in
phase 1, data were recorded 10 minutes after patients were
placed in the knee-chest position (M2).
Data Analysis
In phase 1, a decrease in CO between supine and
knee-chest positions of 30% was expected on the basis of
data from a previous study.19 In phase 2, we anticipated a
reduction of half the CO variation quantified in phase 1,
that is, 15%, similar to that in awake volunteers.26 On the
basis of a statistical significance of 5% and power of 80%,
the power analysis determined that 20 patients were re-
quired.
Data were collected from the LiDCO rapid and Ru-
gLoopII software independently and at different sampling
frequencies. Synchronization between the 2 data sets was,
therefore, required before the analysis. Dedicated software
was developed in Matlab for this task. The delay between
the LiDCO rapid and RugLoopII data were estimated by
the lag of the maximum cross-correlation value between
simultaneous systolic blood pressure values acquired from
both sources. The optimum resampling of RugLoopII data
were placed in the same timeline as those from the LiDCO
rapid, achieving the highest maximum cross-correlation
value. Data synchronization was successful in all recordings.
Normalized cross-correlations between systolic blood pres-
sure time series acquired by both devices were above 0.9 for
all recordings. For data analysis, 1-minute duration win-
dows around each of the above-defined study moments were
utilized, and the average of the observed values computed
for each window.
Statistical analysis incorporated a full factorial
model in a 2-way mixed analysis of variance (ANOVA)
analysis to compare the mean differences of the measured
variables, considering the main effect moment (between
subjects), the main effect phase (within subjects), and their
interactions. The normality assumption was tested by
the Shapiro-Wilk test of normality, and the sphericity
FIGURE 1. Moments of the study. Phase 1 included three moments—M0, M1, and M2. Phase 2 included four moments—M0, M1,
M1′, M2. BIS indicates bispectral index; Ce, effect-site concentration; CO, cardiac output; HD, hemodynamic; KC, knee-chest
position; LOC, loss of consciousness; remif, remifentanil.
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assumption was investigated by the Mauchly’s Test of
sphericity. Further post hoc testing (ANOVA and t test
with Bonferroni correction) was conducted to compare
moments and phases. The assumption of homogeneity of
variances was investigated using Levene’s test. Alternative
nonparametric testing (Friedman, Wilcoxon Signed-Rank,
and Mann-Whitney U ) was also conducted in order to
investigate the impact of any deviation from the assump-
tions of the parametric tests. In this analysis, the statistical
conclusions at the 5% level from parametric and non-
parametric tests were concordant. Data for moment and
phases are expressed as mean±SD. All statistical analyses
were conducted in SPSS software (version 25) (IBM,
New York). P-values <0.05 were considered statistically
significant.
RESULTS
Twenty patients were included in the study: 9 in phase
1 and 11 in phase 2. Patient demographics and baseline
values are shown in Table 1. There were no significant
differences in patient demographics or American Society of
Anesthesiologists’ status between the 2 phases. There was
also no statistically significant difference in baseline CO
before induction of anesthesia, or in the estimated propofol
Ce at LOC between phases 1 and 2.
Phase 1 Results
Anesthesia induction reduced CO by 25.6% (averaged
percentage reduction for all patients with respect to the
baseline—M0 to M1), from 7.37±1.85 to 5.39±1.33 L/min
(P<0.01). Positioning patients from supine to knee-chest
caused a further average decrease in CO of 17.2% (M1 to
M2), from 5.39±1.33 to 4.39 ±1.17 L/min (P= 0.026). The
total decrease in CO from baseline (M0) to after knee-chest
positioning (M2) was, on average, 38.4%, from 7.37±1.85
to 4.39 ±1.17 L/min (P< 0.01) (Table 2).
There was no statistically significant association be-
tween CO changes and age, weight, sex, initial CO, or
propofol Ce at LOC at any moment in phase 1. Systolic,
diastolic, and mean arterial blood pressure decreased sig-
nificantly from baseline at both M1 and M2 (P< 0.01).
From M0 to M1, on average, systolic blood pressure de-
creased by 30.7%, diastolic pressure by 28.9%, and mean
pressure by 30.3%. From M0 to M2, systolic blood pres-
sure decreased by 42.4%, diastolic pressure by 39%, and
mean pressure by 33.1%. Stroke volume was also reduced
from baseline (M0) to M1 by 16% and from baseline to
M2 by 37% (both P< 0.01). Systemic vascular resistance
and heart rate decreased from M0 to M1 by 4.4% and
11.7%, respectively, and increased from M1 to M2 by
7.3% and 11.8%, respectively. Pulse pressure and stroke
volume variability increased significantly from M1 to M2,
from 9% to 21% and 13% to 21%, respectively (Fig. 2).
Ephedrine boluses of 5 mg were required in 4 patients: 1
bolus per patient after induction and one bolus after
positioning in 2. BIS values did not differ between M1 and
M2. Propofol Ce at LOC was 5.03 ± 0.75 μg/mL (Table 1).
Phase 2 Results
The average decrease in propofol Ce following LOC
was 27.5% (maximum decrease 43% (7.0 μg/mL), mini-
mum decrease 19% (2.7 μg/mL). At M1 (10 min after
LOC), CO decreased by 19.8% (average percentage of all
subjects with respect to the baseline, from M0 to M1),
from 7.24± 2.34 to 5.64 ± 1.65 L/min (P< 0.01). After M1,
the planned second reduction in propofol target Ce was
17.2% (the percentage decrease in CO identified during
positioning in phase 1). Following this second reduction at
M1′, CO was 5.56 ± 1.74 L/min, which was not sig-
nificantly different from that at M1. From M1′ to M2 (10
min after KC position), CO decreased on average by 31%
(from 5.56± 1.74 to 3.91 ± 1.89 L/min, P< 0.01), and from
M0 to M2 by 46.9% (7.24 ± 2.34 to 3.91 ± 1.89 L/min,
P< 0.01) (Table 2). There was no statistically significant
association between CO changes and age, weight, sex,
initial CO, or propofol Ce at LOC, at any moment in
phase 2. Ephedrine was not administered in any patient.
Systolic, diastolic, and mean blood pressure were
decreased significantly from baseline at all moments
(P< 0.01). From M0 to M1, on average, systolic blood
pressure decreased by 22.2%, diastolic blood pressure by
15.1%, and mean pressure by 19%. From M2 to M0,
systolic blood pressure decreased by 42.5%, diastolic
pressure by 24.6%, and mean pressure by 34.3%. Stroke
volume was also reduced significantly from baseline, on
average, by 18.6% from M0 to M1, and 47% from M0 to
M2 (both P< 0.01).
Systemic vascular resistance was slightly increased
after induction of anesthesia (by 1.9%) and significantly so
(23.9%) after knee-chest positioning (P< 0.05). There was
no change in heart rate. Changes in pulse pressure variation
(26% vs. 29%) and stroke volume variation (23% vs. 24%)
after knee-chest positioning were similar (Fig. 3). In phase 2,
propofol Ce at LOC was 4.34±1.52 μg/mL (Table 1).
Phase 1 Versus Phase 2 Results
The reduction in CO following induction of anes-
thesia was not significantly different between phases: a
25.6% reduction during phase 1 and 19.8% during phase 2.
There was also no difference in the reductions in CO fol-
lowing the knee-chest position between the 2 phases:
17.2% and 31% in phases 1 and 2, respectively. Only
TABLE 1. Patients’ Demographics and Baseline Values
Characteristics Phase 1 Phase 2
Age (y) 49.3± 8.7 59.7± 13.5
Sex (F/M) (n) 6/3 6/5
Height (cm) 161.6± 9.0 167.8± 12.4
Weight (kg) 70.9± 13.9 77.3± 11.6
Body mass index (Kg/m2) 27.0± 3.5 27.4± 3.0
ASA classification I/II (n) 3/6 2/9
Cardiac output (baseline) (L/min) 7.4 ± 1.8 7.2± 2.3
Propofol Ce at LOC (μg/mL) 5.03± 0.75 4.34± 1.52
Demographics and baseline values of the patients for phase 1 and phase 2.
Values are expressed as mean ±SD or number (n).
ASA indicates American Society of Anesthesiologists; Ce, effect-site concen-
tration; LOC, loss of consciousness.
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TABLE 2. Hemodynamic Variables, Bispectral Index Values, and Effect-Site Concentration (Ce) of the Drugs




































7.4 ± 1.8 5.4 ± 1.3$ 4.4± 1.2¥ −25.6 −38.4 7.2± 2.3 5.6 ± 1.6$ 5.6± 1.7 3.9 ± 1.9¥# −19.8 −46.9 < 0.001 0.867 0.514
Cardiac index
(L/min/m2)








153.2 ± 16.4 106.7 ± 18.2$ 87.1 ± 13.0¥ −30.7 −42.4 170.1± 23.0 131.5 ± 23.1$ 129.7± 32.2 95.9 ± 24.6¥# −22.2 −42.5 < 0.001 0.018 0.363
MAP
(mmHg)








97.0 ± 19.6 81.2 ± 16.6$ 59.7 ± 14.8¥,# −16.0 −37.1 99.8 ± 20.8 81.7 ± 24.0$ 76.7 ± 23.9 54.4 ± 24.2¥# −18.6 −47.0 < 0.001 0.939 0.453
Heart rate
(beats/min)
77.0 ± 15.4 66.9 ± 12.4 74.5 ± 13.8 −11.7 −2.5 72.6 ± 18.4 70.5 ± 16.1 73.3 ± 13.1 72.3 ± 15.3 −0.7 1.5 0.035 0.879 0.208
SVV (%) — 9.4 ± 5.9 21.1 ± 8.6¥ — — — 17.1 ± 10.8 23.2 ± 13.3 24.5 ± 9.9 — — < 0.001 0.295 0.235
PPV (%) — 13.6 ± 5.2 27.9 ± 11.2# — — — 20.3 ± 14.6 26.4 ± 15.7 29.2 ± 21.1 — — < 0.001 0.636 0.293
BIS 94.0 ± 2.2 61.8 ± 15.2$ 42.3 ± 15.1# −34.2 −55.5 95.3 ± 2.6 49.9 ± 9.8$ 46.5 ± 7.5 37.7 ± 8.7¥# −48.0 −22.7 < 0.001 0.056 0.165
Propofol Ce
(μg/mL)
— 3.84± 0.63 2.53± 0.79# — −34.1
(M1 to M2)
— 2.63± 0.54 2.47± 0.57 2.13± 0.47# — −19.0
(M1 to M2)
< 0.001 0.018 0.003
Remifentanil
Ce (ng/mL)
— 2.36± 0.42 1.11± 0.35# — −51.2
(M1 to M2)
— 1.85± 0.66 1.12± 0.20 1.15± 0.48# — −21.3
(M1 to M2)
0.001 0.132 0.107
Results are presented as mean± SD.
ANOVA indicates analysis of variance; BIS, bispectral index; MAP, mean arterial pressure; PPV, pulse pressure variation; SVR, systemic vascular resistance; SVV, stroke volume variation.
The significant differences (5% level) were calculated based on repeated measures of ANOVA post hoc pairwise testing with Bonferroni correction. There were no significant differences between M1 and M1′. The
percentage of variation is computed as (Mi/Mj−1)×100. For example (M1/M0−1)×100 is the percentage of each variable increase/reduction from M0 to M1. Phase comparison presents the P-value of the 2-way ANOVA
analysis with regard to between-subjects effect (phase) and the moment(s) exhibiting significant differences at 5% level.
$significant differences between M0 and M1.
¥significant differences between M0 and M2.





























































postinduction changes in systolic blood pressure were
significantly different between the 2 phases, being higher
in phase 2 compared with phase 1 (P< 0.001) (Table 2).
There was a nonsignificant trend toward higher systemic
vascular resistance increases from baseline in phase 2
(Table 2 and Fig. 4). There were no differences in BIS
between phases (Table 2).
The relationship between CO and mean arterial pres-
sure variation in both phases of the study were assessed using
correlation coefficients: In phase 1, r=0.34 for variation
betweenM0 andM1, and r=0.004 for variation betweenM0
and M2 (not significant). For phase 2, r=0.56 for variation
between M0 and M1 (not significant) and r=0.76 between
M0 and M2 (P<0.01).
Comparing drug concentrations between the 2 phases,
propofol Ce was significantly lower in phase 2 at M1, but
there were no significant differences for remifentanil Ce
(Table 2). In order to test for any interaction between age and
FIGURE 2. Hemodynamic changes (% from baseline) from M0 to M1 and M2 during phase 1. CO indicates cardiac output; HR,
heart rate; MAP, mean arterial blood pressure; PPV, pulse pressure variation; SV, stroke volume; SVR, systemic vascular resistance;
SVV, stroke volume variation; Sys, invasive systolic blood pressure.
FIGURE 3. Hemodynamic changes (% from baseline) from M0 to M1, M1′, and M2 in phase 2. CO indicates cardiac output; HR,
heart rate; MAP, mean arterial blood pressure; PPV, pulse pressure variation; SV, stroke volume; SVR, systemic vascular resistance;
SVV, stroke volume variation; Sys, invasive systolic blood pressure.
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response to changes in propofol Ce, we further considered the
ANOVA adjusted for age and found no significant age
interaction terms for all the variables reported in Table 2.
Furthermore, adjustment for age did not impact the
significance of the differences between moments and phases.
DISCUSSION
In this study, induction of anesthesia was associated
with significant reductions in CO. In phase 1, CO de-
creased by 25.6% and, in phase 2, by 19.8% despite the
predefined reduction in propofol following LOC. Despite
this, systolic blood pressure was higher at M1 (after in-
duction of anesthesia) in phase 2 compared with phase 1
(P= 0.018). Hypotension after induction of anesthesia is
relatively common, and it is more prevalent during the late
postinduction period and before skin incision (5 to 10 min
after).2,13 Although this is often believed to be clinically
inconsequential, there is some evidence that even small
reductions in blood pressure can be associated with poor
patient outcomes.4,5,27 Intraoperative management of
hypotension is usually guided by conventional hemody-
namic monitoring (systolic and mean blood pressures), but
these variables might not identify low levels of blood flow
and oxygen delivery, which, even if time limited, may lead
to major perioperative complications and longer hospital
lengths of stay.17,28 In our study, there was no correlation
between mean arterial pressure and CO, especially during
phase 1. Therefore, it appears that arterial pressure might
not be the best variable to guide anesthesia management,
and vasoactive drug or fluid therapy.
Placing anesthetized patients in the knee-chest posi-
tion resulted in further decreases in CO in both phases of
our study. It had been expected that the preplanned pro-
pofol reduction of 17% before positioning would attenuate
any further reduction in CO, but, in the event, it did not,
there was a 31% reduction in CO associated with knee-chest
positioning in phase 2. Possibly the measured reduction in
CO (17%) during knee-chest positioning identified in phase
1, which was the basis for the second planned reduction in
propofol Ce during phase 2, was impacted by the ephedrine
boluses administered in some patients to maintain blood
pressure within predetermined targets. Using an esophageal
Doppler in anesthetized patients after knee-chest position-
ing, Bennarosh et al19 reported a 35% reduction in CO,
although the change after anesthesia induction was not
quantified. That study also indicated that propofol target
plasma concentrations to maintain BIS values constant were
reduced (by 30%), but there was no intervention in the an-
esthesia protocol. A study in awake volunteers reported a
15% to 20% reduction in CO after the knee-chest position,26
likely related to a decrease in venous return due to blood
sequestration in lower limbs.
In our study, assessment at M1′ in phase 2 allowed
us to interpret the hemodynamic changes in more detail.
The only intervention between M1′ and M2 was posi-
tioning, confirming that the knee-chest position is an in-
dependent factor for CO reduction. Our data suggest that
this likely occurred because of decreased venous return,
because the reduction in stroke volume we observed was
not compensated by an increase in heart rate. The absence
of a heart rate response may be related to propofol’s ac-
tion on the baroreflex.1,29 In addition, the changes in
systemic vascular resistance in phase 2 were not sufficient
to compensate for the decrease in stroke volume.
Pulse pressure variation and stroke volume variation
are hemodynamic markers of hypovolemia in mechan-
ically ventilated patients, and they might also be useful in
the standard prone or knee-chest positions; Biais et al30
demonstrated that fluid responsiveness could be predicted
FIGURE 4. Changes in cardiac output, mean arterial pressure,
stroke volume, and systemic vascular resistance during phases
1 and 2.
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in the prone position. In our study, increases in pulse
pressure and stroke volume variations suggest that anes-
thetized patients in the knee-chest position behave as if
they are hypovolemic. Stroke volume decreased from M1
to M2 by 24.6% in phase 1 and by 30.1% in phase 2. We
believe that this represents a relative hypovolemia because
of reduction in venous return secondary to accumulation
of the intravascular volume in the lower extremities. These
findings suggest that vasopressor and chronotropic drugs,
such as ephedrine, may be the best treatment for the de-
crease in CO caused by the knee-chest position in anes-
thetized patients.
As expected, propofol Ce was significantly lower in
phase 2 compared with phase 1 because of the planned re-
ductions. There were no differences in remifentanil Ce, BIS
values, or hemodynamic parameters except for systolic
blood pressure. Thus, we can conclude that, in the knee-
chest position, patients may require a lower propofol Ce to
maintain anesthesia. Importantly, there were no cases of
awareness in our study. These findings suggest that plasma
concentrations might be higher than estimated by the
models we used,14,15 and influenced by CO variations, as
previously observed by Keyl et al.31 The increased plasma
propofol concentrations may be due to a reduction in pro-
pofol distribution or due to reduced hepatic clearance dur-
ing hypotensive episodes.32,33 The effects of the prone
position and its variants on cerebral blood flow and cerebral
oxygenation are also not well quantified.34 Although cere-
bral oxygenation in anesthetized patients in the prone po-
sition can be maintained within safe margins, there is
evidence of impairment of autoregulation,35 and this might
be reflected in low BIS values. However, our hypothesis that
reducing propofol Ce promptly after LOC and immediately
before knee-chest positioning could attenuate the fall in CO
and thereby minimize adverse effects, including cerebral
effects, was not supported by the findings of our study.
Nevertheless, our study does confirm that hemody-
namic changes in anesthetized patients do not necessarily
result from excessive anesthesia, as BIS was similar in both
phases. Further, because our study was conducted in
healthy patients (American Society of Anesthesiologists
classification I and II) scheduled for an elective procedure
for either lumbar disc herniation or lumbar spinal canal
stenosis, the hemodynamic changes we identified could not
be attributed to blood loss, hypovolemia, or cardiac disease.
Many authors have highlighted the need to optimize high-
risk patients during the perioperative period, guided by
advanced hemodynamic monitoring.5,7,36,37 We believe that
anesthetized patients in the knee-chest position could also
benefit from such monitoring, including before induction of
anesthesia, when it is possible to establish a baseline for
trend evaluation during the entire surgical procedure.38
The present study has several limitations. The sam-
ple size may be considered small. However, the ANOVA
analysis was comprehensive, with 3 measures compared in
each individual and between the 2 phases. The definition
of the moments of data analysis presented quite a chal-
lenge, but we defined the 10-minute period of stabilization
following induction of anesthesia and KC positioning
according to previous literature.2,19 The fact that this
was a nonrandomized study may also be considered a
limitation. However, data from phase 1 was essential to
quantify the interventions during phase 2. Finally, as this
was a short duration study limited to the early intra-
operative period, it was not possible to determine whether
any of the hemodynamic changes we identified might
impact patient outcomes.
CONCLUSIONS
Induction of anesthesia and the knee-chest position are
associated with significant reductions in CO. Physicians
should be aware that the knee-chest position is an in-
dependent risk factor for hemodynamic changes, and that
reductions in propofol concentration immediately after LOC
and before positioning do not attenuate them. We found no
correlation between mean arterial pressure and changes in
CO, suggesting that blood pressure alone may not be a useful
variable to guide anesthesia management or vasoactive drug
or fluid therapy in this context. The use of minimally invasive
COmonitors in anesthetized patients may aid in the detection
of important hemodynamic changes in the knee-chest posi-
tion and guide therapy in order to minimize predictable risks.
We plan further work using a simulation program to educate
clinical teams in a structured approach with regard to the
anesthesia management of patients scheduled for surgery in
the knee-chest position.
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Abstract
Background: Anesthesia induction and maintenance with propofol can be guided by target-controlled infusion (TCI) systems using
pharmacokinetic (Pk) models. Physiological variables, such as changes in cardiac output (CO), can influence propofol pharmacoki-
netics. Knee-chest (KC) surgical positioning can result in CO changes.
Objectives: This study aimed to evaluate the relationship between propofol plasma concentration prediction and CO changes after
induction and KC positioning.
Methods: This two-phase prospective cohort study included 20 patients scheduled for spinal surgery. Two different TCI anesthesia
protocols were administered after induction. In phase I (n = 9), the loss of consciousness (LOC) concentration was set as the propofol
target concentration and CO changes following induction and KC positioning were quantified. In phase II (n = 11), based on data
from phase I, two reductions in the propofol target concentration on the pump were applied after LOC and before KC positioning.
Propofol plasma concentrations were measured at different moments in both phases: after induction and after KC positioning.
Results: Schnider Pk model showed a good performance in predicting propofol concentration after induction; however, after KC
positioning, when a significant drop in CO occurred, the measured propofol concentrations were markedly underestimated. In-
tended reductions in the propofol target concentration did not attenuate HD changes. In the KC position, there was no correlation
between the propofol concentration estimated by the Pk model and the measured concentration in plasma, as the latter was much
higher (P = 0.013) while CO and BIS decreased significantly (P < 0.001 and P = 0.004, respectively).
Conclusions: Our study showed that the measured propofol plasma concentrations during the KC position were significantly un-
derestimated by the Schnider Pk model and were associated with significant CO decrease. When placing patients in the KC position,
anesthesiologists must be aware of pharmacokinetic changes and, in addition to standard monitoring, the use of depth of anesthe-
sia and cardiac output monitors may be considered in high-risk patients.
Keywords: Hemodynamics, Knee-Chest Position, Propofol Pharmacokinetics, Anesthesia, Infusion Pumps
1. Background
Anesthesia induction and maintenance with propo-
fol can be guided by target-controlled infusion (TCI) sys-
tems that incorporate a pharmacokinetic (Pk) model into
a computer-controlled pump, allowing for intravenous
anesthetics titration and targeting plasma and effect-site
drug concentrations (1, 2). However, propofol pharmacoki-
netics can be influenced by changes in physiological vari-
ables, such as cardiac output (CO), as propofol is a high-
clearance drug. In addition, an increase in the propofol
plasma concentration could also result in hemodynamic
(HD) changes (3-7). These HD variations can modify the
TCI modeling ability to predict propofol concentrations (8)
such that up to a 60% precision error can occur as the great-
Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License
(http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly
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est bias after induction in the early maintenance phase (9).
Patients’ positioning in the knee-chest (KC) position
(Figure 1) following anesthesia induction further reduces
venous return and CO (10, 11). Physiological changes and
complications associated with surgical positions, such as
the prone and KC positions, have been studied extensively
(12, 13).
Researchers previously observed that patients in the
prone position required less propofol than those in the
supine position. In the present study, it was hypothe-
sized that predicted propofol effect-site (Ce) and predicted
plasma concentrations (Cp) would not be accurate when
these HD changes occur, especially after KC positioning (4,
5, 14). It was also hypothesized that applying two different
TCI anesthesia protocol reductions in propofol infusion,
one performed after induction and the other one before
positioning, would reduce the prediction error and atten-
uate the CO changes.
2. Objectives
The aim of this study was to quantify the variations
in propofol plasma concentrations (Cm), both after induc-
tion and after KC positioning, and correlate them with Cp
by the Schnider Pk model. CO was continuously measured
with a minimally invasive CO monitor, LiDCO rapid® (15-17)
(LiDCO Ltd., Cambridge, UK).
3. Methods
After obtaining the REB approval and written informed
consent, we recruited consecutive neurosurgical patients
scheduled for lumbar spinal surgery in the KC position. A
two-phase prospective observational study was conducted.
Figure 1. KC surgical position, a variant from the prone position
In the first set of patients (phase I), propofol plasma con-
centrations were measured and compared with concentra-
tions predicted by the Schnider Pk model and the changes
in CO following induction and KC positioning were quan-
tified. In the second set of patients (phase II), based on
the data from the first set of patients, two propofol target
concentration reductions were planned immediately after
anesthesia induction and before positioning.
Propofol plasma concentrations were also measured
and compared with predicted and the changes in CO fol-
lowing induction and KC positioning were also quantified,
as done in phase I. The exclusion criteria included patients
with severe ischemic heart disease, congestive heart fail-
ure, atrial fibrillation or flutter, body mass index (BMI) > 35
kg.m-2, dementia, history of drug abuse or addiction, and
preoperative midazolam. A careful physical examination
was performed on each patient to exclude potentially diffi-
cult airway and ischemic peripheral arterial disease.
3.1. Anesthesia Protocol
A crystalloid intravenous infusion at 400 mL.h-1 was
initiated once patients arrived in the operating room,
which continued until the end of anesthesia induction
and maintained at 200 mL.h-1 throughout the surgery. Pa-
tients received American Society of Anesthesiologists (ASA)
standard monitoring, including depth of anesthesia mon-
itoring with bispectral indexTM (BISTM brain monitoring,
Medtronic, USA) and neuromuscular block monitoring
with the train of four stimulations on the right hand. Be-
fore induction, a left radial artery catheter was placed with
local anesthesia to measure invasive blood pressure and
LiDCO rapid® was connected to collect CO and other hemo-
dynamic parameters every second. This device used the
same algorithm as the LIDCO plus® system, but it required
neither lithium dilution nor calibration, as it used nomo-
grams based on patients biometric parameters to estimate
cardiac output and stroke volume. In a separate com-
puter, RugLoopII© software (DEMED website, Temse, Bel-
gium) was used to drive remifentanil and propofol pumps
(AlarisTM Asena, BD, UK) and to collect data every five sec-
onds while connected to the patient monitor (Aisys®, GE
Healthcare, USA). At this moment, the first blood sam-
ple, called “Baseline”, which was free of drugs, was col-
lected and all pharmacological and HD parameters were
recorded. Anesthesia induction commenced with remifen-
tanil (20 µg.mL-1) by the TCI mode to achieve a predicted
effect-site target concentration (Ce) of 2.5 ng.mL-1 (Minto
pharmacokinetic model). Propofol (1%) was then started at
200 mL.h-1 in the TCI view until the loss of consciousness
(LOC). The LOC was considered when the patient failed to
open the eyes following name-calling and tapping on the
forehead. At the moment of LOC, propofol predicted effect-
site concentration (Ce) was noted from RugLoopII© soft-
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ware. The propofol protocol in patients from P1 and P2 was
different, as explained in detail in the following.
3.2. Experimental Protocol
3.2.1. Phase I (P1)
After LOC, the propofol concentration was switched
from the TCI view to the TCI mode with Schnider Pk model
at a target concentration equal to the Ce at LOC. Tracheal
intubation was accomplished following neuromuscular
blocking drug administration (rocuronium 0.6 mg.kg-1)
and patients’ lungs were mechanically ventilated with O2
and air mixture to achieve SpO2 of > 98%, tidal volume of 8
mL.kg-1, and the respiratory rate adjusted to normocapnia.
Remifentanil Ce was reduced to 1 ng.mL-1 until surgical in-
cision. Anesthesia maintenance was guided by BISTM (40-
60) and HD parameters by the anesthesiologist. The sec-
ond blood sample was collected 10 min after LOC and then
patients were positioned in the KC position carefully and
using a ProneView® platform for the head. The third blood
sample was collected and parameters were registered 10
minutes after performing the KC position before incision
(Figure 2). At this point, phase I of the study was completed.
3.2.2. Phase II (P2)
After LOC, the propofol concentration was switched
from the TCI view to the TCI mode at a Ce target lower than
Ce at LOC, calculated using a formula described in detail in
supplementary file Appendix 1, which relates the Ce of LOC
with the Ce that results in maintaining BIS between 40 and
60.
Tracheal intubation and ventilation settings were sim-
ilar to phase I. Remifentanil Ce was changed to 1 ng.mL-1
until surgical incision. The second blood sample was col-
lected 10 minutes after LOC. A second reduction of propofol
Ce was performed with the same magnitude as the CO vari-
ation observed in phase I patients and 2 minutes later, the
third blood sample was collected. Afterward, patients were
placed in the KC position as described in phase I. Ten min-
utes after KC positioning and before incision, the fourth
blood sample was collected (Figure 3). At this point, phase
II of the study was completed.
3.3. Plasma Propofol Sampling
During the study period, 3 mL arterial blood sam-
ples were collected from the left radial artery into hep-
arin containing tubes for propofol and propofol metabo-
lites quantification in the plasma according to the pro-
tocol. The propofol plasma concentration and its free
metabolites were determined by gas chromatography
mass-spectrometry with some adjustments (18, 19).
The accuracy and bias of model predictions were cal-
culated from differences between propofol Cm and Cp for
each individual patient expressed as the prediction error
(PE) (3), median prediction error (MDPE), and median ab-
solute performance error (MDAPE). An acceptable perfor-
mance was characterized by MDPE of less than 20% (-20 to
20%) and MDAPE of 20% - 40%. A model is most accurate
when the values of MDPE and MDAPE are close to zero. In
TCI, the typical accepted values are 10% to 20% for bias and
around 30% for accuracy (20).
3.4. Data Analysis
Data were collected using LiDCO rapid® and
RugLoopII© software that gathered data independently
and with different sampling frequencies; therefore, syn-
chronization between data was mandatory for this study.
Dedicated software was developed in Matlab® for the
interface. For data analysis, one-minute duration windows
were considered around each of the above-defined study
moments and the average of the observed values was
computed for each window. The statistical analysis was
considered as a full factorial model in a two-way mixed
ANOVA analysis used to compare the mean differences
of the measured variables, considering the main effect
“Moment” (within-subjects: same individual at different
moments), the main effect “Phase” (between-subjects:
different individuals, a group compared to another) and
their interactions “Moment × Phase”. A P value of < 0.05
was considered statistically significant. Further post hoc
testing (ANOVA and t-test with Bonferroni correction)
was conducted to compare “Moments” and “Phases”. The
results were expressed as mean± standard deviation (SD).
All statistical analyses were conducted in SPSS® software V.
25 (IBM, New York, USA).
4. Results
Twenty patients (9 in phase I and 11 in phase II) were in-
cluded in this study. Patients’ demographic data are pre-
sented in Table 1.
Data concerning the drugs used, HD parameters, and
BIS values are reported in Table 2. In phase I, there were
no protocolled propofol target reductions; thus, propofol
Ce target concentrations were manually modified by the
anesthesiologist, guided by BIS and HD parameters (Figure
2). Propofol Ce and Cp were statistically different between
all moments (P < 0.001) but measured propofol did not
show any differences (Table 2).
There were significant HD changes after anesthesia in-
duction and after KC positioning with respect to the base-
line in both phases (Figure 4). In phase I, CO fell by 25.6%
after induction and 38.4% after KC position, compared to
the baseline.
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Anaesthesia induction: 
Ce remifentanil,2.5 ng.ml-1




Propofol = LOC Ce. BIS and 
HD guided anaesthesis.


































































































Figure 2. Relationship between propofol effect-site concentration (Ce) (µg.mL-1) and moments of the study (time) in phase I (baseline, SP1, and KC). HD, hemodynamic; LOC,
loss of consciousness; KC, knee-chest; SP1, supine.
Table 1. Demographics and Baseline Values of the Subjects in Phase I and Phase IIa
Characteristics Phase I Phase II
Age, y 49.3 ± 8.7 59.7 ± 13.5
Sex (f/m) 6/3 6/5
Height, cm 161.6 ± 9.0 167.8 ± 12.4
Weight, kg 70.9 ± 13.9 77.3 ± 11.6
Body Mass Index, kg.m-2 27.0 ± 3.5 27.4 ± 3.0
ASA classification I/II 3/6 2/9
Cardiac output (baseline), L.min-1 7.4 ± 1.8 7.2 ± 2.3
Propofol Ce at LOC, µg.mL-1 5.03 ± 0.75 4.34 ± 1.52
Time to LOC, min 3.76 ± 0.80 3.05 ± 1.22
Abbreviations: ASA, American Society of Anesthesiologists; LOC, loss of con-
sciousness; Propofol Ce, propofol effect-site concentration.
aValues are expressed as No. or mean ± SD.
In phase II, after induction, propofol target Ce was set
at a value below the Ce at LOC, based on the formula pre-
sented earlier in methods. The average decrease in propo-
fol Ce following LOC was 27.5%, with a maximum of 43%
(prop Ce LOC = 7.0µg.mL-1) and a minimum of 19% (prop Ce
LOC = 2.7 µg.mL-1). The second reduction in propofol was
performed in all patients that was equal to the CO reduc-
tion measured in patients from the phase I following KC
positioning (17.2%) (Figure 3). Propofol Ce and Cp were sta-
tistically different between all moments, except between
SP2 and KC moment (Table 2). Measured propofol showed
a statistical difference between SP2 and KC moment (P =
0.013).
In phase II, despite propofol Ce reductions, CO reduced
significantly from baseline 46.9%, after induction 19.8%
and after KC position 31% (Figure 4). From moment SP1 to
moment SP2, HD parameters did not vary.
In both phases, there was no statistical association be-
tween CO changes and age, weight, gender, baseline CO,
and propofol Ce at LOC (P > 0.05). A correlation was
found between baseline CO and propofol requirements
for LOC (propofol infused volume until LOC), with statis-
tical significance in phase II (r = 0.76; P = 0.006). Be-
tween phases, there were significant differences in propo-
fol Ce (P = 0.005) and propofol Cp (P = 0.015) at the SP1 mo-
ment. Propofol infused volume was statistically different
between all moments and between phases, except for LOC.
A total of 71 arterial blood samples were obtained,
propofol concentrations were measured, and the pre-
dicted error was calculated for each patient, as shown in
Table 3.
At the SP1 moment, there were no differences between
4 Anesth Pain Med. 2019; 9(5):e96829.
























































































































Ce Remifentanil 2.5 ng.ml-2
Propofol 200 ml.h-1 Until LOC
Propofol Maintenance Dosis: 
% of LOC Ce. Calculated by a
Formula 
1% Reduction of Propofol
2 7 10 12 17 20 23 27 30 33
Figure 3. Relationship between propofol effect-site concentrations (Ce) (µg.mL-1) and moments of the study (time) in phase II (baseline, SP1, SP2 and KC). HD, hemodynamic;
LOC, loss of consciousness; KC, knee-chest; SP1, supine; SP2, supine after the second reduction in propofol infusion.
Table 2. Drug Data, Cardiac Output, and BIS Values for Each Moment and Each Phasea , b
Drugs Data and
Variables (Units)
Phase I (N = 9) Phase II (N = 11) Two-Way ANOVA (P Value)
Baseline SP1 KC Baseline SP1 SP2 KC Moment Phase Moment × Phase
Propofol (µg.mL-1 )
Ce 5.03 ± 0.75 (LOC) 3.84 ± 0.63c 2.53 ± 0.79e 4.34 ± 1.52 (LOC) 2.92 ± 0.64c 2.47 ± 0.57 2.20 ± 0.51e < 0.001* 0.054 0.352
Cp - 3.83 ± 0.74 2.48 ± 0.86e - 2.97 ± 0.68 2.46 ± 0.58 2.24 ± 0.58e < 0.001* 0.06 0.083
Cm - 3.61 ± 1.14 3.31 ± 2.11 - 2.96 ± 0.81 2.68 ± 0.72 3.90 ± 1.90f 0.455 0.961 0.162
Remifentanil (ng.mL-1 )
Ce - 2.36 ± 0.42 1.11 ± 0.35e - 1.85 ± 0.66 1.12 ± 0.20 1.15 ± 0.48e < 0.001* 0.132 0.107
Propofol Inf. volume
(mL)
12.46 ± 2.44 (LOC) 22.53 ± 4.09c 37.09 ± 8.07d , e 9.63 ± 4.09 (LOC) 15.86 ± 6.10c 19.36 ± 6.71 27.15 ± 8.63d , e , f < 0.001* 0.014* 0.034*
BIS 94.0 ± 2.2 61.8 ± 15.2c 42.3 ± 15.1e 95.3 ± 2.6 49.9 ± 9.8c 46.5 ± 7.5 37.7 ± 8.7d , e < 0.001* 0.056 0.165
Cardiac output
(L.min-1 )
7.4 ± 1.8 5.4 ± 1.3c 4.4 ± 1.2d 7.2 ± 2.3 5.6 ± 1.6c 5.6 ± 1.7 3.9 ± 1.9d , e < 0.001* 0.867 0.514
Abbreviations: Ce, effect-site concentration; Cm, measured plasmatic concentration; Cp, predicted plasmatic concentration; Inf., Infused; LOC, loss of consciousness; KC, knee-chest; SP1, supine; SP2, supine after the second reduction in
propofol infusion.
a Values are expressed as mean ± SD.
b The superscripts c, d, e, and f indicate significant differences (5% level) on repeated measures ANOVA post hoc pairwise testing with Bonferroni correction (*).
c Significant differences between Baseline and SP1.
d Significant differences between Baseline and KC;
e Significant differences between SP1 and KC;
f Significant differences between SP2 and KC.
Cp and Cm (P = 0.559) and there was a statistical correlation
between them (r = 0.640; P = 0.002). At the KC moment,
there was an underestimation of propofol plasma concen-
trations from the Pk model in both phases (34% in phase
I and 74% in phase II) (Figure 5). Cp and Cm were statisti-
cally different (P = 0.005) and there was no statistical corre-
lation between them (r = 0.374; P = 0.104). In both phases,
BIS values did not differ between phases (P = 0.165) (Table
2). There were no cases of patient awareness. Linear regres-
sion analysis revealed no statistically significant relation-
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Figure 4. HD changes (cardiac output, mean arterial pressure, stroke volume, and
systemic vascular resistance variation) in phase I and phase II.
ship between BIS values and propofol Cm or BIS values and
cardiac output at any moment.
5. Discussion
In the present study, a propofol TCI system with
Schnider Pk model was used to drive a propofol pump that
showed a marked underestimation of plasma propofol lev-
els in patients placed in the KC position. The study also
showed that the KC position was associated with signif-
icant hemodynamic changes, as a reduction in CO from
baseline was observed (Figure 4). After induction, the
Schnider Pk model showed a good performance in Cp pre-
diction (Table 3). Also, there was a statistical correlation be-
tween Cp and Cm. In the KC position, when the greatest
Table 3. Performance Analysis of the Propofol Schnider Pk Model Expressed in Me-
dian Prediction Error (MDPE) and Median Absolute Performance Error (MDAPE) for
Each Moment and Phase (%)
Moments
Propofol Pk Model Performance (%)
MDPE MDAPE
Phase I
SP1 -6% (-49 to 20) 15% (1 to 49)
KC 28% (-35 to 114) 35% (6 to 114)
Phase II
SP1 13% (-43 to 45) 20% (4 to 45)
SP2 18% (-45 to 56) 32% (0 to 56)
KC 48% (-44 to 270) 48% (6 to 270)
Abbreviations: KC, knee-chest; SP1, supine; SP2, supine after the second reduc-
tion in propofol infusion.
CO reduction occurred, Schnider Pk model performance
was not accurate, as propofol Cp was not correlated with
Cm and it was markedly underestimated by 34% in phase
I and 74% in phase II. Also, in the KC position, the MDPE
and MDAPE values calculated at this moment did not show
a good performance.
In phase II, between moment SP2 and moment KC,
when propofol Cp and propofol Ce concentrations were
unchanged and the only intervention performed on pa-
tients was KC positioning, it was observed an increase in
the measured propofol concentrations (P = 0.013) and a de-
crease in BIS values (P = 0.004) (Figure 5).
The influence of CO on the pharmacokinetic models to
predict propofol plasma concentrations during TCI had al-
ready been discussed by some authors (6). It can be spec-
ulated that the difference between the predicted and mea-
sured propofol concentrations in patients with lower CO
is most likely related to a decrease in total propofol clear-
ance, but further data are still needed to correlate CO or
liver blood flow and plasma clearance of propofol. Upton
et al. (14) reported an inverse relationship between CO and
propofol concentrations after a short propofol infusion in
an ovine model. Myburgh et al. (8) observed the same re-
lationship during longer propofol infusions in a high-CO
state induced by catecholamine infusion in the ovine. Ku-
rita et al. (5) confirmed, in a swine model, that Cp was in-
versely correlated with changes in CO during constant in-
fusion. We also plotted the relationship between measured
Cp and the inverse of CO, but we did not observe any sta-
tistical association. It must be highlighted that most of
the published studies were performed in animal models,
with no studies in humans. Recently, Keyl et al. (4) found
that Schnider Pk model markedly underestimated Cp in
patients with impaired left ventricular function.
In phase II of our study, we found a statistical correla-
6 Anesth Pain Med. 2019; 9(5):e96829.
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Figure 5. Predicted (green line) and measured (blue line) propofol concentrations (µg.mL-1) at SP1, SP2 (phase II), and KC moment in both phases. KC, knee-chest; SP1, supine;
SP2, supine after the second reduction in propofol infusion.
tion between propofol infused volume until LOC and base-
line CO, showing that CO is a determinant to infer the ini-
tial concentrations of propofol for anesthesia induction
(14).
In the present study, we expected a correlation be-
tween propofol infused volume and CO fall. Comparing
both phases, propofol consumption (propofol infused vol-
ume) was much lower in phase II than in phase I (P = 0.034)
(Table 2). Also, patients in both phases did not show differ-
ences in BIS values and other parameters; thus we can con-
clude that patients in the KC position need lower propo-
fol concentrations. Nevertheless, propofol targeted reduc-
tions did not attenuate the CO fall when placing patients
in the KC position, as the authors previously hypothesized.
The results suggest that planned decrements in propofol
target Ce did not correspond to a decrease in Cm (Figure
5), as in phase II, after two reductions, the underestimation
increased at the KC moment.
Furthermore, hemodynamic changes should be
avoided in high-risk patients, even for short periods,
as they are associated with poor outcomes (21-23). The
present study also showed an important finding that even
in ASA 1 and 2 patients, significant HD changes may occur
after the KC position.
5.1. Limitations
The present study has several limitations. ANOVA was
quite comprehensive, with three measures compared in
each individual and between the two groups. However, re-
garding propofol concentrations, the sample size may be
considered small. The definition of the moments of data
analysis was a challenge. We defined a 10-minute period
stabilization following induction and KC positioning ac-
cording to the literature (10, 24). The fact that this was
a non-randomized study may be considered a limitation.
However, we needed data from the first phase to determine
the intervention in the second phase.
5.2. Conclusions
Our study showed that the measured propofol con-
centrations, after hemodynamic changes associated with
the KC position, were much higher than the values pre-
dicted by Schnider Pk model. Planned propofol reduc-
tions did not attenuate the underestimation error from
the Pk model. When placing patients in the KC position, BIS
values decreased and the measured propofol concentra-
tions increased. Our results suggest that the CO variation
was responsible for the pharmacokinetic phenomenon de-
scribed above. In high-risk patients placed in the KC po-
sition, anesthesiologists must be aware of these pharma-
cokinetic changes and, in addition to standard monitor-
ing, the use of depth of anesthesia and cardiac output
monitors may be considered. Further work is planned in
an educational area with a simulation program to prepare
surgical teams to a structured and careful approach for
these patients.
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Design of an interface for teaching
cardiovascular physiology to anesthesia
clinicians with a patient simulator
connected to a minimally invasive cardiac
output monitor (LiDCO rapid®)
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Abstract
Cardiovascular physiology can be simulated in patient simulators but is limited to the simulator monitor curves and
parameters, missing some important data that today is known as essential to fluid management and therapeutic
decision in critical ill and high-risk surgical patients. Our main objective was to project and implement a
unidirectional communication channel between a pre-existing patient simulator and a minimally invasive cardiac
output monitor (LiDCO rapid®); a monitor that connects to real patients and interprets the arterial wave. To connect
the patient simulator to the hemodynamic monitor, firstly, we had to assess both systems and design a
communication channel between them. LiDCO monitor accepts as an input an analog voltage varying between 0 V
and 5 V and that every volt is directly proportional to a blood pressure (mmHg) value ranging from 0 mmHg (0 V)
to 500 mmHg (5 V). A Raspberry Pi 0 (Rpi0) with a WIFI chip integrated was needed and added to a digital
analogue converter connected to the board. We designed a system that allowed us to collect, interpret and modify
data, and feed it to the LiDCO rapid® monitor. We had developed a Python® script with three independent threads
and a circular buffer to handle the data transmission between both systems. The LiDCO hemodynamic monitor
successfully received data sent from our setup like a real patient arterial wave pulse and interpreted it to estimate
several hemodynamic parameters, as cardiac output, stroke volume, systemic vascular resistance, pulse pressure
variation, and stroke volume variation. The connection between the patient simulator and the LiDCO monitor is
being used to create arterial curves and other hemodynamic parameters for clinical scenarios where residents and
anesthesiologists can simulate a variety of unstable hemodynamic conditions, preparing them to face similar
situations with real patients in a safe environment and with their own monitors.
Keywords: Clinical simulation, Cardiovascular physiology, Medical education, Healthcare innovation
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: danielachalo@gmail.com
1Department of Physiology and Pharmacology, Faculty of Medicine,
University of Salamanca, Salamanca, Spain
2Department of Anesthesiology, Centro Hospitalar do Baixo Vouga, Aveiro,
Portugal
Full list of author information is available at the end of the article
Chaló et al. Advances in Simulation            (2020) 5:16 
https://doi.org/10.1186/s41077-020-00134-0
Introduction
Technological advances in medicine are an actual fact and
the new generation of anesthesia clinicians must be pre-
pared, since the very beginning of their residence, to use
advanced technology in several equipment: monitors and
patient ventilators, ultrasound and airway management
devices. Also, experienced anesthesiologists need to be up-
dated and must know how to use the new devices and
how to teach to younger clinicians and residents. Active
learning strategies and simulation technologies are already
used with medical students [1, 2] and residents [3], and
their benefits and advantages on students’ learning cogni-
tive and behavioural skills are well recognised [4, 5].
Simulation-based learning can also be helpful to develop
healthcare professional’s knowledge, skills, and attitudes
while protecting patients from unnecessary risks [6]. An-
esthesiologists pioneered the use of patient simulators in
training programs all over the world [7, 8]. In Portugal,
since 2018, the Anesthesiology Medical Council estab-
lished a program with recommended courses using simu-
lation as a teaching tool.
In recent years, significant progress has been made
with perioperative technology, namely, with minimally
invasive cardiac output (CO) monitors such as the
LIDCO rapid® (LiDCO Ltd., Cambridge, UK) [9–11].
This device uses the PulseCO™ algorithm, without cali-
bration, which converts the blood pressure arterial wave
to its constituent parts of flow (cardiac output and
stroke volume) and systemic vascular resistance (SVR).
The PulseCO™ algorithm is scaled to each patient with a
nomogram using age, height, and weight. The PulseCO™
algorithm is reliable in unstable patients and in patients
on vasoactive drugs. This CO monitor also estimates:
cardiac index, stroke volume index, pulse pressure vari-
ation (PPV), and stroke volume variation (SVV).
Patient simulators (PS) are an essential tool as part of
the methodology in which lifelike situations are simu-
lated and clinicians are exposed to scenarios in a safe en-
vironment which later promote self-reflection during the
debriefing phase, in order to improve the clinician’s
knowledge and skills. This patient simulator, METIman®
Pre-Hospital (CAE Healthcare), is an advanced patho-
physiological simulator that can represent different clin-
ical scenarios, including important variations in
hemodynamics, by modifying parameters such as heart
contractility, aortic impedance, systemic, and pulmonary
vascular resistances. Nevertheless, in most cases, ad-
vanced hemodynamic parameters, such as stroke vol-
ume, pulse pressure variation (PPV), and stroke volume
variation (SVV), are not represented in the simulator’s
monitors, resulting in a technological limitation. Patient
simulators are also limited because of their inability to
integrate with real clinical equipment, as minimally inva-
sive cardiac output monitors.
Our main objective in this study was to project and
implement an unidirectional communication channel
between a pre-existing patient simulator METIman® Pre-
Hospital from CAE Healthcare and a minimally invasive
cardiac output monitor, LiDCO rapid® [12], thus being
able to simulate a set of conditions on the patient
Fig. 1 Diagram connection between the Raspberry Pi and the MCP4725 12-bit DAC
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simulator and make the LiDCO monitor respond to
those same conditions as if a real patient was being
monitored. This integration will further allow us to de-
velop clinical scenarios and train clinicians in advanced
hemodynamic monitoring using simulation.
Material and methods
To achieve the goal of connecting the patient simulator
to the LiDCO rapid® monitor, firstly, we had to assess
both systems and design a communication channel be-
tween them. To perform the hardware integration, we
used a Raspberry Pi Zero W®. The Raspberry Pi Zero W®
is a small computer on a board that runs a distribution
of Linux and can be programmed on demand using Py-
thon®. We also used a DAC (digital to analogue con-
verter) board with a MCP4725 12-bit DAC (Fig. 1) [13,
14]. This is an I2C (serial protocol for two-wire interface
to connect low-speed devices like microcontrollers) con-
trolled by DAC that can run on a 0–5 V output to gen-
erate and send a 0–5 V continuous signal to the LiDCO
monitor input. For the connection between the DAC
and the monitor, it used a BNC Female Jack Terminal
Block compatible with the coaxial input line of the
LiDCO monitor. The patient simulator data can be
accessed by connecting the Raspberry Pi and the patient
simulator control unit over its internal network and
doing a SQL (Structured Query Language) request to its
main processing unit, obtaining the systolic blood pres-
sure (SBP), diastolic blood pressure (DBP), and the heart
rate (HR), values it generates once a second. Alongside,
we worked with the LiDCO development team and
established that the LiDCO monitor accepts as an input
an analog voltage varying between 0 V and 5 V and that
every volt is directly proportional to a blood pressure
(BP) (mmHg) value ranging from 0 mmHg (0 V) to 500
mmHg (5 V). Therefore, a circuit was designed to allow
the Raspberry Pi to collect, interpret, and modify the
data from the PS (input) and feed it into the LiDCO
monitor (output) (Fig. 2). As the PS did not have a way
to export the BP pulse wave values, we created an
Fig. 2 Diagram of the collecting and processing data from the patient simulator, to the Raspberry Pi and DAC, and to the hemodynamic monitor
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algorithm program in Python®, in which we gathered
and normalized the amplitude of a standard BP pulse
wave (0 mmHg–1 mmHg) from a real patient and
resized it to the value range acquired from the PS (DBP/
SBP). The Python® script had three independent threads
and a circular buffer to handle the data transmission be-
tween both systems. The first thread (main) was respon-
sible for setting some local variables that store function
values and to initiate the two secondary threads and the
circular buffer. The buffer contains the normalized array
with the BP pulse wave information. The second thread
connected to the PS query the HR, SBP, and DBP on 1-s
intervals making it available to the third thread. The
third thread received the buffer BP pulse wave values,
performed the necessary calculations, and wrote the final
values on the DAC (adjusted to 0–5 V) with an adjusted
frequency to match the HR value on the PS (Fig. 3). Var-
iables transmitted from the patient simulator are pre-
sented at Table 1.
Results
The communication between the patient simulator and
the LiDCO monitor was successfully achieved. Data
from the PS (HR, SBP, DBP) was extracted on a fre-
quency of 1/s (1 Hz). This information was processed,
resampled, and sent to the LiDCO monitor to be inter-
preted as if data from a real blood pressure pulse wave
was being processed. The LiDCO hemodynamic monitor
successfully received and interpreted the data sent from
our setup as if it was received from a real patient, as it
can be seen in the Electronic Supplementary Material
(ESM.1). The interface algorithm used a normalized vec-
tor as a reference, i.e., a sample of BP waveform (signal),
acquired from a patient without pathology, recorded at
250 Hz and 47 bpm (beats per minute). Then, the signal
from the normalized vector was adjusted to the HR and
to the BP from the PS, and the amplitude of the max-
imum signal and minimum signal corresponded to the
SBP and to the DBP, respectively (Fig. 4).
Discussion
Cardiovascular physiology can be simulated in patient
simulators but is limited to the simulator monitor curves
and parameters, missing some important data essential
to fluid management and goal-directed therapy (GDT)
in critically ill and high-risk surgical patients. The pur-
pose of hemodynamic monitoring is to identify varia-
tions in cardiovascular parameters and intervene before
major complications occur, including organ failure or
death. During surgery, fluid therapy should be targeted
according to physiological measures and maintained
using fluids or vasopressors once normovolemia has
been established, so that tissue oxygenation would not
be compromised [11, 15].
This tool is important to train not only basic cardio-
vascular physiology but also hemodynamic variations
during anesthesia phases: induction, positioning, con-
trolled hypotension, and other surgical conditions asso-
ciated with hemodynamic compromise (orthopedic
surgery, vascular surgery, major abdominal surgery) [16].
It can also be used to test enhanced recovery after sur-
gery and emergency protocols associated with situations
with hemodynamic instability like massive hemorrhage,
septic shock, trauma, and obstetric hemorrhage. The im-
plementation of GDT with the use of minimally invasive
monitors to guide perioperative practice has become
rapidly established and accepted over the last few years,
from central venous pressure until stroke volume vari-
ation or pulse pressure variation. All minimally invasive
Fig. 3 Algorithm for the connection setting with the three threads
Table 1 Output variables transmitted from the PS to the DAC
Variable Signal type Units Inferior limit Superior limit
HR Digital (decimal) bpm 0 350
SBP Digital (decimal) mmHg NA NA
DBP Digital (decimal) mmHg NA NA
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monitors have different characteristics and layouts, so
clinicians should train on their own monitor to be famil-
iar with the parameters and its interpretation, to
minimize errors and provide a better and safe
healthcare.
Patients with cardiac or vascular pathology can display
different hemodynamic curves, especially in those with
heart diseases, abnormal contractibility, rhythm condi-
tions, and valve-related pathologies. This fact should be
taken into consideration when developing scenarios.
There is a limitation related to the fact that we used a
normalized vector to simulate the BP waveform, so that
can only vary the amplitude of the BP wave and the HR,
but not the wave configuration. Despite this limitation,
the methodology still has advantages as it requests a few
number of parameters from the simulator that can be, in
future versions, provided from a control station, allowing
the training even without the need of a patient
simulator.
Authors also believe the interface could be used with
other PS or other monitors. Nevertheless, this possibility
is dependent on the ability to communicate with the
simulator to request the three variables used (HR, SBP,
and DBP). If the PS is different and the transmitted
Fig. 4 Connection between the Raspberry Pi and the LiDCO monitor
Fig. 5 Clinical scenario in the simulation center
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signal is analog, the approach would be easier, because
the only request would be a 0–5 V analog input trans-
mitted from the probe side.
Conclusions
Anesthesiologists should be trained on their own cardiac
output monitors, so they can interpret fast and easier
their parameters, minimize errors, and provide a better
and safe healthcare. The interface between the patient
simulator and LiDCO rapid® monitor is now being used
to teach anesthesiologists and residents with success,
allowing a safe environment in a clinical simulation sce-
nario (Fig. 5). In the near future, authors believe that the
interface can be developed for other patient simulators,
and it can also be used to teach other healthcare pro-
viders in an interprofessional educational program.
Supplementary information
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1186/s41077-020-00134-0.
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generated by the connection between the patient simulator and the
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